Experts & associés

Disease area: Prostate cancer

Biography:
Vérane Achard is a specialist in Radiation Oncology at the University Hospitals of Geneva, Switzerland. After obtaining her master’s degree in Engineering at the INP-Phelma in Grenoble, France, she finished her PhD in Physics for Life Sciences at the French Alternative Energies and Atomic Energy Commission (CEA) in 2009. She completed residencies at the departments of Radiation Oncology of the Grenoble Alpes University Hospital in France, and the University Hospitals of Geneva in Switzerland, before obtaining her MD in Radiation Oncology in 2019. The fields of interest of Dr. Achard include high-precision radiotherapy techniques (SBRT, IGRT, VMAT) and genitourinary cancer treatment, specifically treatment of oligometastatic prostate cancer. Dr. Achard received the Scientific Association of Swiss Radiation Oncology (SASRO) 2019 best academic presentation award and young researcher grant. She has (co-)authored 10 peer-reviewed publications.

See COI

Disease area: Prostate cancer

Biography:
Dr. Neeraj Agarwal is a Professor of medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah, Salt Lake City, UT, USA. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI. Dr. Agarwal is an internationally recognized physician scientist in the field of genitourinary cancers. He is the overall study chair of multiple Phase I/II and Phase III trials, and serves as a steering committee member of numerous other trials. He has received SWOG Young Investigator Award, the William D. Odell Young Investigator Award, and a National Cancer Institute Cancer Clinical Investigator Team Leadership Award. After receiving his medical training at the All India Institute of Medical Sciences in New Delhi, he completed a residency in internal medicine and a fellowship in geriatric medicine at the University of Iowa, followed by a hematology-oncology fellowship at HCI. Dr. Agarwal has authored more than 350 peer-reviewed articles and book chapters. He serves as a panel member for the NCCN guideline committees for bladder and kidney cancers. He is an advisor to the Oncology Drug Advisory Committee and the United States Food and Drug Administration, and leads early therapeutics in the SWOG genitourinary cancers committee. He holds numerous scientific communications leadership roles, including chief editor of the ASCO Daily News, specialty editor for ASCO’s cancer.net site, and editorial board member of several journals, including Journal of Clinical Oncology and European Urology. He also serves as a member of the ASCO Genitourinary Cancers Advisory Panel. Recently, Dr. Agarwal was appointed as the Senior Director for Clinical Research Innovation, directly reporting to the cancer center director at the Huntsman Cancer Institute.

Disease area: Breast cancer

Biography:
Dr. Elisa Agostinetto is a medical oncologist and researcher in the field of breast cancer. She earned her medical degree in Italy, at University of Udine. She completed her training in medical oncology in Milan, Italy, and afterwards she moved to Brussels, Belgium, where she is currently pursuing an advanced research fellowship at Institut Jules Bordet - Université Libre de Bruxelles. She is a member of the European Society of Medical Oncology (ESMO), of the American Society of Clinical Oncology (ASCO), and of the Belgian Society of Medical Oncology (BSMO); she is a young investigator in the EORTC Breast Cancer Working Group, and she is a Steering Committee member of the Young Cancer Professionals within the European Cancer Organization. She is author of more than 50 articles published in peer-reviewed scientific journals, including JAMA, Nature Reviews Clinical Oncology, Lancet Oncology, Annals of Oncology, European Journal of Cancer, and ESMO Open. Her research works have been presented in several international oncology conferences, including ASCO, ESMO and San Antonio Breast Cancer Symposium. She is the recipient of several prestigious national and international awards.

See COI

Disease area: Renal Cell Carcinoma

Biography:
Professor Laurence Albiges is a medical oncologist and head of the Department of Oncology at Gustave Roussy. Her main areas of interest are new therapies for metastatic kidney cancer and rare forms of renal cell carcinoma. She is currently developing translational research programs on these topics. Laurence Albiges is the author of numerous publications in recognized scientific journals. She is associate editor of the journal European Urology Oncology. As a result of her research work, she has received several distinctions, awards and funding, including the Conquer Cancer Foundation Merit Award at the ASCO Genitourinary Symposium in 2015 and the Unicancer-Fondation de France grant. Her research on biomarkers of response to immunotherapy is funded by a K-RTP award. Prof. Laurence Albiges is a member of the GETUG steering committee and of the EAU (European Association of Urology) guidelines panel for kidney cancer. She is involved in the ESMO (European Society for Medical Oncology) where she has been a member of the scientific committee of the congress since 2017. She belongs to the cancer committee of the French association of urology and the scientific board of the EIKCS (European International Kidney Cancer Symposium) and EMUC (European Multidisciplinary Congress on Urological Cancers). She is also a member of the scientific board of the KCA (Kidney Cancer Association).

See COI

Disease area: Renal Cell Carcinoma

Biography:
Carolina Alves Costa Silva obtained her medical degree from the Federal University of Bahia, Brazil in 2012. After her graduation, she obtained a position in the internal medicine residency program at Hospital das Clínicas and subsequently in the oncology fellowship program at Instituto do Câncer do Estado de São Paulo, both part of of the Academic Health Center of the University of Sao Paulo, Brazil. After her fellowship, she joined a multidisciplinary cancer team as a clinical oncologist at Núcleo de Oncologia da Bahia, a partner center of Oncoclínicas Brazil. She participated at DUERTECC program (Gustave Roussy, France) from 2018-2019 with the project “Metabolic impact of Cabozantib treatment in patients with metastatic renal cell carcinoma”, under the supervision of Dr Laurence Albiges. Following her research work on the impact of sarcopenia and the gut microbiome in kidney cancer, she received a grant from A.R.Tu.R. (Association pour la Recherche sur les Tumeurs du Rein) in 2019 and the young physician award Jean Klastersky in 2020. She started her PhD at laboratory U1015 at Gustave Roussy in 2020, under the supervision of Prof Laurence Zitvogel, Dr Laurence Albiges and Dr Lisa Derosa. Their work aims to improve knowledge and understanding the mechanism of the impact of gut microbiome in kidney cancer.

See COI

Disease area: Bladder cancer, Renal Cell Carcinoma

Biography:
Tom Arends obtained his medical degree in 2012 from the Radboud University Medical Centre in Nijmegen, The Netherlands. After his graduation, he started as a PhD candidate at the Urology Department. He defended his thesis on bladder cancer in June 2016 and simultaneously started as a urology resident. He won several scientific prizes with his thesis. In 2017, he received the “Residents’ Best Scientific Paper Award” for a publication in European Urology. At the end of 2020, he will finish his urology residency and start as urologist in Amersfoort, The Netherlands.

See COI

Disease area: Bladder cancer, Renal Cell Carcinoma

Biography:
Aristotelis Bamias, MD, PhD, is Professor at the Medical School, University of Athens, in Greece. He studied Μedicine in the Medical School of the University of Athens and trained in Ιnternal Μedicine and Μedical Οncology in the UK where he served as Lecturer in Medical Oncology at the University of London. He is affiliated with the Department of Clinical Therapeutics of the University of Athens at the Alexandra Hospital in Athens, where he is in charge of the laboratory of the Oncology Unit. He is a founding member and Chair of the Hellenic Genito-Urinary Cancer Group (HGUCG). He is a member of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and the Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Professor Bamias has been a member of the European Society of Medical Oncology (ESMO) Faculty for Genitourinary Cancer since 2012 and he is currently chairing this group. He is a member of the ESMO Educational Committee and a member of the Scientific Committee of the ESMO 2016-2019 Congresses. His main research focus in oncology is urogenital and gynaecological tumours and he has been invited speaker in many international Congresses on subjects related to these malignancies. A member of several international advisory boards and steering committees of international trials, he has published more than 240 original papers and reviews in peer-reviewed journals with more than 8000 citations by other authors and a current h-index of 44.

See COI

Disease area: Renal Cell Carcinoma

Biography:
Philippe Barthélémy is a medical oncologist, working since 2010 in the medical oncology department of the Strasbourg Cancer Institute (ICANS), resulting from the alliance between the Strasbourg University Hospitals and the Paul Strauss Center in Strasbourg. He carries out significant clinical activity related to urogenital cancers, for which he is the referent. He is also clinical manager of the Molecular RCP of Strasbourg set up in 2017 and a member of ESMO and GETUG.

See COI

Disease area: Breast cancer

Biography:
Dr Nicolò Matteo Luca Battisti is a Consultant Medical Oncologist in the Breast Unit of The Royal Marsden NHS Foundation Trust, London, UK, where he is also Clinical Lead of the Senior Adult Oncology Programme. He gained his medical degree at the University of Milan, Italy in 2009 and he completed his specialist training at the University of Milan and National Cancer Institute of Milan, Italy in 2015. He obtained a research degree (MD[Res]) within the Breast Cancer Research Division of the Institute of Cancer Research of London, UK in 2022 with a thesis focusing on of the management of common malignancies in older adults under the supervision of Dr Alistair Ring and Professor Stephen Johnston. Dr Battisti completed the European Society for Medical Oncology Leaders Generation Programme in 2022. He has an Italian Board Certification in Medical Oncology and is on the UK General Medical Council Specialist Register (Medical Oncology). He is also Member of the Royal College of Physicians. He spent the last year of his specialist training working with Dr Martine Extermann and Dr Lodovico Balducci at the Senior Adult Oncology Program of the Moffitt Cancer Center of Tampa, Florida, USA. In 2016, Dr Battisti joined the Breast Unit of The Royal Marsden NHS Foundation Trust, where he currently works with Dr Alistair Ring and Professor Stephen Johnston. Dr Battisti’s main clinical and research interests are breast oncology and geriatric oncology. His main areas of investigation are comorbidities, comprehensive geriatric assessment, quality of life and prediction of anticancer treatment toxicity in older patients with cancer. He authored several publications and book chapters in the fields of geriatric, breast and thoracic oncology. Dr Battisti is President of the International Society of Geriatric Oncology (SIOG) and has served as Co-Chair and subsequently Chair of the Young Interest Group of SIOG. He also serves as Treasurer of the European Cancer Organisation and Co-Chair of its Inequalities Focused Topic Network. Dr Battisti also serves as Executive Committee Member of the European Society of Breast Cancer Specialists (EUSOMA). He is a member of the Elderly Task Force of the European Organisation for Research and Treatment of Cancer (EORTC) and member of the Cancer and Aging Research Group (CARG) Advocacy Committee and Clinical Implementation Core. He is a member of the Clinical Steering Group of the National Audit of Breast Cancer in Older Patients (NABCOP) in the UK. Dr Battisti was presented the Arti Hurria Award at the 2019 San Antonio Breast Cancer Symposium for his research on the use of chemotherapy in older patients with early breast cancer enrolled on the Bridging The Age Gap study and in 2021 he was presented the Dario Cova Award from the Italian Group of Geriatric Oncology for his contribution to the field of geriatric oncology.

See COI

Disease area: Prostate cancer

Biography:
Anders Bjartell MD, PhD FEBU graduated from Lund University Medical School, Sweden, in 1986. He was a research fellow at the National Institutes of Health in Bethesda, Maryland, USA, from 1988 to 1989, and received his PhD in Medical Cell Research from Lund University in 1990. After training at the University Hospital in Malmö, he became Specialist in Urology in 1998, and received his Fellows of the European Board of Urology (FEBU) diploma in 1999. He was appointed Associate Professor at Lund University in 1995. Professor Bjartell was a Clinical Investigator at the Department of Urology, Memorial Sloan Kettering Cancer Center in New York, USA, from 2005 to 2007, Associate Editor for European Urology from 2005 to 2012, and he is past-president and board member of the European Association of Urology (EAU) Section of Urological Research (ESUR) and board member of EAU Guidelines Office. Professor Bjartell was appointed Chairman of the EAU Research Foundation in 2017 and since 2016 he is Board member of the EAU Guidelines Office. In 2006, Professor Bjartell became full Professor in Clinical Urology, and Senior Consultant at Skåne University Hospital in Malmö. In 2012, he was appointed Assistant Dean at the Medical Faculty, Lund University. Professor Bjartell is also a national principal investigator for several trials of new drugs in castration resistant prostate cancer and Head of the clinical trial unit at the Urology Department at Skåne University Hospital. He leads a research group in translational prostate cancer research with long term experience in prostate cancer biomarkers. His research also encompasses clinical projects on robotic surgery, imaging, and drug development. He has participated in several EU-sponsored prostate cancer projects, and he has published more than 258 peer reviewed original articles.

See COI

Disease area: Bladder cancer

Biography:
Dr. Jérémy Blanc is a medical oncologist in training and PhD student in the field of genito-urinary cancer. He earned his medical degree in Belgium, at Université Libre de Bruxelles. He is working at Jules Bordet Institute (HUB), Brussels, since 2020 and has started a PhD in 2022 on bladder cancer and immunotherapy, funded by the F.R.S-F.N.R.S. Aspirant fellowship. He is a member of the Belgian Society of Medical Oncology (BSMO), of the European Society of Medical Oncology (ESMO) and of the American Society of Clinical Oncology (ASCO). He is the co-founder of the Young Oncologist Committee (YOC) of the BSMO and member of the Renal Cell Carcinoma group in the Immucan project in collaboration with the EORTC. He recently received the Conquer Cancer Merit Award 2024 from the ASCO Foundation.

See COI

Disease area: Prostate cancer

Biography:
Dr Alberto Bossi is currently Head of the Urology and Prostate Brachytherapy Unit at the Gustave Roussy Cancer Institute in Villejuif, France. His professional career started in Italy where he was born: he graduated in Medicine and Surgery in 1988 and specialized in Radiotherapy and Diagnostic Radiology in 1992 at the University of Pavia. After a Clinical Fellowship at the Dept of Radiation Oncology at the Academic Medical Centre in Amsterdam he worked in Como and Milan. In 2001 he was appointed Adjunct Clinical Head at the Department of Radiation Oncology of the University Hospital in Leuven, Belgium where he worked till 2006 before moving to IGR. Dr Bossi is member of several scientific societies, including ESTRO, ASTRO, EAU. He has served as Coordinator of the Genito-Urinary Working Group of the EORTC in 2006. He is the Course Director of the Multidisciplinary ESTRO-EAU-ESMO Teaching Course on Prostate Cancer and teacher at both the ESO (European School of Oncology) and EAU (European Association of Urology) Prostate Courses. He is PI and co-PI (Principal Investigator) of two major European Phase III trials on Prostate Cancer and has published over 40 papers in peer-reviewed journals. Dr Bossi is reviewer for several journals including the IJROBP, European Urology, Radiotherapy and Oncology, Annals of Oncology.

See COI

Disease area: Bladder cancer, Renal Cell Carcinoma

Biography:
Sergio Bracarda, MD is currently the Director of the Division of Medical Oncology, Department of Oncology, Azienda Ospedaliera S. Maria, Terni, Italy. Dr Bracarda graduated from the School of Medicine, University of Perugia in 1986, specialised in Medical Oncology at the Sacred Heart Catholic University of Rome, Italy, and in Urology at the University of Perugia, where he later became a Resident in the Department of Medical Oncology. Prior to taking up his current position, Dr Bracarda was first Junior, then Senior Registrar/Consultant Oncologist, in the Department of Urology, University of Perugia, then Senior Oncologist and Section Chief of Oncology-Urology in the Medical Oncology Division, Policlinico Hospital, Perugia and Director of the Medical Oncology Unit, Department of Oncology and Prostate Unit in Arezzo, Italy. His current research interests are genitourinary oncology, and particularly prostate cancer, renal cell carcinoma and urothelial cancer, central nervous system and gastrointestinal tumours, treatment approaches that combine biological agents with traditional drugs and schedule optimization. Dr Bracarda has published 151 articles in peer-reviewed journals, more than 700 abstracts, and a number of text book chapters. He was Board Member (Councillor) of the Italian Association of Medical Oncology (AIOM) and is Board Member of the Italian Society for Urology-Oncology (SIUrO). Moreover, he is a Reviewer for several Oncological and Urological journals. Dr Bracarda’s society memberships include the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the European Society for Medical Oncology (ESMO), the European Association of Urology (EAU), the Italian Society of Medical Oncology (AIOM), the Italian Society of Urology (SIU) and the Italian Society for Urology-Oncology (SIUrO).

See COI

Disease area: Breast cancer

Biography:
Etienne Brain has been working since 1998 as a medical oncologist at Institut Curie, Paris and Saint-Cloud, France. He obtained his MD in Medical Oncology from Paris-Descartes University in 1995, as well as a PhD in Pharmacology (2005) after initiating (pre)clinical works on alkylation at the Dana Farber Cancer Institute and Boston University, Boston, USA (1995-1996). He received a diploma to supervise research from Saint-Quentin University, Versailles, France (2010) and in Management and Health Economics from Bocconi University, Milan, Italy (2014-2015). Etienne Brain is strongly involved both in breast cancer research and management of older cancer patients, as best epitomized by the large phase III program ASTER 70s (Adjuvant Systemic Treatment for ER+ HER2- breast carcinoma in women over 70 according to genomic grade). As an active member in the Unicancer organization, he is the current chair of the EORTC Breast Cancer Group. He is a board member of the Breast International Group (BIG) and the European Breast Cancer Conference (EBCC). He is also a member of the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) steering committee. He is former president of SIOG (International Society of Geriatric Oncology). Since 2014, he is the co-organizer of the SIOG International Course in Geriatric Oncology with the Catholic University of the Sacred Heart in Treviso, Italy. He is (co)author of several publications in peer reviewed journals, including the JAMA, Lancet Oncology, Annals of Oncology and Journal of Clinical Oncology. He is a member of the Editorial Boards of the Breast and the Journal of Geriatric Oncology. He is an active member of ESMO and ASCO.

See COI

Disease area: Prostate cancer

Biography:
Dr Douglas Brand MBBChir PhD FRCR MRCP is a UK-based Clinical Oncology Specialist Registrar working clinically at the Royal Surrey County Hospital, Surrey, with honorary academic appointment at the Institute of Cancer Research, London. Graduating in medicine at the University of Cambridge in 2011, he has completed Academic Clinical Fellowship clinical research positions at The Christie Hospital, Manchester, UK 2013-2015 and The Royal Marsden Hospital, London, UK 2016-2017. He completed his PhD in 2021 based at the Institute of Cancer Research, UK, focussing on predictors of toxicity in prostate hypofractionated radiotherapy trials. From March 2022 he will be based at UCL as a Clinical Lecturer in Clinical Oncology, with a research focus on AI applications in oncology care.

See COI

Disease area: Prostate cancer

Biography:
Dr Briganti works as Urologist at Vita-Salute University, San Raffaele Hospital, Milan, Italy. He is a member of several national and international associations as well as being a member of the European Urology Editorial Board at Large. He is a fellow of the European Board of Urology and is also a reviewer of the main urological journals. He is author and co-author of more than 150 papers published in peer reviewed, indexed Journals. His main clinical interests are urological oncology, including development and validation of several prognostic staging tools, and sexual medicine, including erectile dysfunction and male sexual health. He has contributed to the development of several multi-institutional data-bases for prostate cancer staging and outcomes which have been used for improving currently available prediction models.

See COI

Disease area: Breast cancer

Biography:
Laurence Buisseret, MD, PhD, is a medical oncologist at the Institut Jules Bordet, Brussels, Belgium. She earned a medical degree from the Université Libre de Bruxelles (ULB) in 2007 and then trained in medical oncology with a focus on breast cancer at the Institut Jules Bordet. From 2014 to 2016, she worked as a research fellow at the Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CR-CHUM), Canada, in a laboratory specialized in the design of targeted therapies using immune strategies in preclinical models and translational research in immuno-oncology. After obtaining her PhD degree in 2017, she started working in the Medical Oncology Clinic and in the Breast Cancer Translational Research Laboratory (BCTL) at the Institut Jules Bordet. Her clinical and laboratory research focuses on cancer immunotherapy and she is involved in the development of therapeutic strategies to strengthen anti-tumor immunity in breast cancer.

See COI

Disease area: Breast cancer

Biography:
Dr Cardoso is the Director of the Breast Unit of the Champalimaud Clinical Center (CCC) in Lisbon, Portugal. She is board certified in medical oncology and internal medicine. Dr Cardoso earned her medical degree at the University of Porto in Portugal and completed fellowships in the Translational Research Unit of the Jules Bordet Institute (IJB) in Brussels, Belgium, and the Department of Molecular and Cellular Oncology at MD Anderson Cancer Center in Houston, Texas. She then worked for 10 years as Assistant Professor at the Medical Oncology Clinic of the IJB and served as the scientific director of the international research network TRANSBIG for 7 years (EU Framework VI). She returned to Portugal in October 2010 to create the Breast Unit of the CCC, leading it to become the 1st certified Breast Unit in Portugal. Her research interests include biology of breast cancer, prognostic and predictive markers, and new anticancer agents, and is involved in many phase I-IV breast cancer clinical trials. Dr Cardoso is also deeply involved in the field of global cancer policy, accessibility and inequalities, and is the founder and President of the Advanced Breast Cancer (ABC) Global Alliance, as well as the founder and chair of the ABC International Consensus Guidelines Conference. She is also active in numerous professional organizations such as ESO, ESMO, ASCO, AACR, EORTC and E.C.O., where she serves on several committees; she was a member of the Board of Directors of ESMO, ECCO and EORTC. She is editor-in-chief of The Breast Journal, associate editor of the European Journal of Cancer, and an editorial board member of several other journals. She has received several educational and research grants from the Breast Cancer Research Foundation, the European Society of Medical Oncology, the European Cancer Organization, the Portuguese Science and Technology Foundation, the Portuguese League Against Cancer, the Portuguese Ministry of Health, the Free University of Brussels, the "Fonds Jean-Claude Heuson", the Fondation Lambeau-Marteau, the Belgian Federation Against Cancer, the Susan G. Komen Foundation, and the European Union. She was awarded the prestigious Order of Santiago da Espada for Scientific Merit, from the President of Portugal, on June 10th 2015. She has also received the Flims Alumni Club (FAC) Lifetime Achievement Award 2011; the Prix Nice - St Paul 2017, for the work developed for Advanced Breast Cancer Patients; the Reach to Recovery International Health Professional Award 2019, for exceptional contributions by a health professional in the field of breast cancer support; the ABC Award 2019, in recognition of her foresight in understanding the importance of advanced breast cancer and for launching a Global Alliance against it, the 2020 Jin Xian-zhai Special Achievement Award, for outstanding contributions to prevention and treatment of human cancer, especially breast cancer, the 2020 European Breast Cancer Science Award/Emmanuel van der Schueren Lecture, the 2021 Umberto Veronesi Memorial Award, and the 2022 ESMO Women For Oncology Award. Dr Cardoso has authored about 350 publications and has presented her work nationally and internationally.

See COI

Disease area: Prostate cancer

Biography:
Elena Castro is a Consultant Medical Oncologist in prostate cancer at Hospital 12 de Octubre in Madrid. Dr Castro studied Medicine and obtained a PhD from the University of Salamanca. After training in Medical Oncology, she completed a fellowship in Cancer Genetics at the Institute of Cancer Research and The Royal Marsden Hospital. In 2013, she moved back to Spain and joined the Prostate Cancer Clinical Research Unit at the Spanish National Cancer Research Center. Dr Castro is a translational clinician-scientist whose research interests span preclinical research to clinical trials. Her work has addressed the clinical implications of genetic and genomic variants in prostate cancer and has been involved in several clinical trials investigating new treatment strategies for patients with advanced prostate cancer.

See COI

Disease area: Bladder cancer

Biography:
Richard Cathomas is head of the division of oncology/haematology at the Kantonsspital Graubünden in Chur, Switzerland, and an associate professor at the University of Zurich (UZH) in Zurich, Switzerland. He earned his MD at UZH and completed his oncology training at UZH and at the University Hospital Southampton NHS Foundation Trust in Southampton, UK. As a dedicated clinician and clinical researcher, Dr Cathomas has acted as coordinating investigator for several national and international trials in the fields of bladder cancer, prostate cancer and testicular cancer. From 2013–2018 he served as president of the Genitourinary Cancers Project Group of the Swiss Group for Clinical Cancer Research (SAKK). He is a member of the SAKK board since 2018. Dr Cathomas is a member of the European Association of Urology (EAU) guidelines committee for muscle-invasive and metastatic bladder cancer and a former member of several scientific committees of the European Society for Medical Oncology (ESMO) annual meeting. He is an active member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the European Organisation for Research and Treatment of Cancer (EORTC). As a medical oncologist specialised in the treatment of urological cancers, Dr Cathomas has published extensively in his field, and is a regular contributor to events and symposia at both the national and international level.

See COI

Disease area: Prostate cancer, Bladder cancer, Renal Cell Carcinoma

Biography:
Dr Amarnath Challapalli is a Consultant Clinical Oncologist at Bristol Cancer Institute, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK, specialising in the management of urological cancers and non-melanoma skin cancers. He undertook his medical and postgraduate training in clinical oncology in India and in the UK, achieving Fellowship of the Royal College of Radiologists. He subsequently completed a PhD at Imperial College, London in January 2014. His research focused on the translation of novel PET tracers looking at cell proliferation, apoptosis and choline metabolism into clinical studies to look at early response assessment to treatment. Dr. Challapalli is the lead oncologist at the Bristol Cancer Institute and is a Prostate Cancer UK (PCUK) Clinical Champion. He has set up the Lutetium PSMA Radioligand service in Bristol. He organises and lectures in the skin cancer study day and has co-developed the skin cancer e-learning module for the Royal College of Radiologists. He has developed and leads the brachytherapy service for non-melanoma skin cancers at the Bristol Cancer Institute. He is a member of the GEC-ESTRO HNS brachytherapy group. Dr. Challapalli is actively involved in research into urological and non-melanoma skin cancers. He is the UK Chief Investigator for the adjuvant Cemiplimab trial in high-risk squamous cell carcinoma (C-POST trial), REACT-Cemi trial and a Co-Chief Investigator of the national multicentre ACE trial in prostate cancer and EPIC trial in penile cancer. His work has been published in peer-reviewed journals and presented at national and international meetings.

See COI

Disease area: Bladder cancer

Biography:
Dr Choudhury is a Reader and Honorary Consultant Clinical Oncologist. She joined The Christie in 2008 specialising in urology and sarcoma and has a strong interest in translational research. In 2013, she decided to focus on radiotherapy-related research in prostate and bladder cancers. She is clinical lead for advanced radiotherapy including the MRLinac project and is co-Group Leader of The Translational Radiobiology Group within the Institute of Cancer Sciences. Dr Choudhury currently undertakes research which aims to optimise and personalise radiotherapy using new techniques or imaging technology to deliver high doses of radiotherapy while minimising side effects and predictive biomarkers to determine which patients benefit from different treatments. Dr Choudhury graduated from Trinity College, Cambridge, but undertook her Clinical Oncology training at the Yorkshire Deanery from 2000-2008. Between 2005 and 2007, she was a Cancer Research UK Clinical Training Research Fellow and she undertook her PhD at the University of Leeds and Princess Margaret Hospital in Toronto, Canada. For her PhD she studied the molecular epidemiology of DNA double strand break repair in bladder cancer and the use of imatinib (a tyrosine kinase inhibitor) for enhanced chemosensitivity and radiosensitivity. She has a lead role in education and training for specialist registrars and clinical fellows. Dr Choudhury is a member of a member of work stream 2 of the National Cancer Research Institute (NCRI) Clinical and Translational Radiotherapy Research Working Group (CTRad) and of the NCRI Bladder Clinical Studies Group. She has also been a member of the NICE bladder cancer guideline development group. Dr Choudhury is the Senior Editor for Genito-urinary cancers for the International Journal of Radiation Oncology • Biology • Physics (The Red Journal).

See COI

Disease area: Bladder cancer

Biography:
Professor Eva Compérat is the head of the Pathology Department in Tenon Hospital, Sorbonne University in Paris. She is member of the French Cancer Committee for Bladder Cancer, and also member of the EAU guidelines in the NMIBC (non-muscle invasive) and MIBC (muscle invasive) committee as well as in the Penile carcinoma guidelines group. She is interested in clinical, but also basic research in the field of uropathology, in which she is specialized. She obtained her MD in Vienna, her PhD in Paris, and the right to lead research groupsC. She studied the molecular and morphologic events in the urothelial carcinogenesis, and is linked to the research group (GRC 5) of Pr Cussenot, Sorbonne University. She has also participated to some substantial works regarding prostate and kidney cancer. Professor Compérat’s primary clinical interest is uropathology, she is known in Europe for her diagnostic skills and receives more than 200 consulting cases from all over the world per year. She has published several book chapters and is one of the co-authors of the WHO 2016 Classification of Tumours of the Urinary System and Male Genital Organs (responsible of 3 chapters, co-author in 4 others). She has authored more than 300 papers and is present in many national and international conferences. Professor Compérat also gives many courses in France and abroad and is involved in many international collaborations as well in Europe, but also with the North American continent.

See COI

Disease area: Bladder cancer

Biography:
Doctor Frederiek D’Hondt graduated in 2008 from the School of Medicine at the University of Ghent, Belgium. Following training in Urology at the OLV Clinic in Aalst and at the Urology Department of the Ghent University, he completed his urologic residency in July 2014. In 2014, he did a clinical fellowship in robotic surgery for prostate and bladder cancer at Karolinska University, Stockholm, Sweden. Since January 2015, he is a full staff member at the Urology Department of the OLV Clinic in Aalst, Belgium. He is a Fellow of the European Board of Urology (FEBU) since 2014. His major interests are urological oncology and minimally invasive and robotic surgery. He is involved as a trainer for robotic surgery at the ORSI Academy and has proctored the start-up of several robotic centres all over Europe He is involved as principal and/or sub-investigator in numerous clinical trials on prostate/bladder/kidney cancer. He has participated in many publications and has given many lectures on robotic surgery in urology.

See COI

Disease area: Breast cancer

Biography:
Evandro de Azambuja, MD, PhD, is the Head of the Medical Support Team (Academic Promoting Team) located at the Jules Bordet Institute in Brussels, Belgium. Dr de Azambuja earned his first PhD from the Federal University of Rio Grande do Sul, Porto Alegre, Brazil, in May 2007 and his second PhD from the Université Libre de Bruxelles (U.L.B.) in December 2015. His principal interest in oncology is breast cancer, especially in the adjuvant/neoadjuvant settings. He is deeply involved in the conduct of large phase III trials in breast cancer (some of them practice changing in breast cancer) such as HERA (adjuvant trastuzumab), ALTTO (trastuzumab and/or lapatinib), APHINITY (trastuzumab with or without pertuzumab), Alexandra (adjuvant atezolizumab in triple negative breast cancer) and – in the neoadjuvant setting – the LORELEI trial which tested the efficacy of PI3K inhibition in combination with endocrine therapy. He is also greatly engaged in studies concerning cancer toxicity of new drugs in oncology as well as in long-term follow-up of patients enrolled in clinical trials with focus in cardiotoxicity. Within the latter context, he was a co-author of guidelines on treatment-related cardiac toxicity by the European Society for Medical Oncology (ESMO) and the European Society of Cardiology (ESC). He was past chair of the survivorship of the Belgian Society of Medical Oncology (BSMO). Dr. de Azambuja was a member of the ESMO Executive Board (2018), and currently is an ESMO Council Member (2019) and the chair of the ESMO Fellowship Committee (mandate started in January 2018). He was a member of the ESMO Young Oncologists Committee (YOC) and the ESMO Press & Media Affairs Committee. He is also a faculty member of the ESMO Leaders’ Generation Program launched in 2016-2017 and Co-chair of this Programme since 2018. He was appointed as a Breast Faculty Member of ESMO in 2017 and was a board member of the BSMO 2015-2019. He was appointed as the chair of the ESMO Leaders Generation Programme Task Force in January 2019. Dr. de Azambuja is also a member of the American Society of Clinical Oncology (ASCO) and the BSMO. He is actively involved in editorial boards of the Journal of Clinical Oncology (JCO), “ESMO Open – Cancer Horizons”, and ESMO Perspective. He has (co)-authored about 200 peer-reviewed articles and 15 book chapters. He has been a member of Education and Scientific Committees of the ESMO, ESMO breast, EBCC and ECCO meetings.

See COI

Disease area: Prostate cancer

Biography:
Professor Alexandre de la Taille is head of Urology Department in CHU Mondor Assistance Publique des Hopitaux de Paris in France and also head of the Inserm U955Eq07 research team on translational research in uro-oncology. He has been involved in uro-oncology for over 15 years and is in charge of the robotic surgery program. His research and clinical activity are focused on Prostate (BPH and cancer). His main research programs include discovery and validation of biomarkers for high-risk prostate cancer patients treated by chemotherapy and hormonal therapies and in inflammation in prostatic benign hyperplasia patients. He teaches and has spoken on urology, robotic surgery and molecular biology of prostate cancer at Paris XII University, IRCAD, American Uologi- cal Association (AUA) meetings and European Association of Urology (EAU) meetings. He is one of the member of the Scientific Office of EAU. He wrote over 411 articles, predominantly focusing on prostate cancer, and his work has received an array of honors, such as the Crystal Matula Award from the EAU and the first prize of research from the American Urological Association (AUA).

See COI

Disease area: Prostate cancer, Bladder cancer

Biography:
Daan De Maeseneer is a medical oncologist trained and graduated from Ghent University, Belgium. His scientific interest in oncology developed while doing research in cell signalling during his master’s degree. His oncology training drove his interest in palliative care and the multidisciplinary approach to cancer care. As a practicing oncologist, his focus lies on urological oncology, especially bladder and prostate cancer.

See COI

Disease area: Prostate cancer

Biography:
Theo M. de Reijke performed his medical training at the Free University in Amsterdam and is working since 1987 as urologist at the Academic Medical Center in Amsterdam. In 2004 he successfully defended his thesis on immunotherapy for bladder cancer. Uro-oncology (prostate and bladder cancer) is his main field of interest and he has been an active member of the European Organization for Research and Treatment of Cancer – Genito Urinary group (EORTC-GU) for many years. After serving as chairman of the prostate cancer subgroup, he was elected as secretary and later as chairman of the EORTC-GU group until June 2009. In the Netherlands, he is the chairman of the prostate cancer guideline committee and he is member of the bladder cancer guideline committee. He is member of different international Urological societies (e.g. EAU, AUA, DGU), reviewer for several international journals and member of scientific boards for different journals. In 2011, he was elected as reviewer of the month for European Urology. He is (co-) author of over 100 publications in peer-reviewed journals and he made contributions to many book chapters. He organised several scientific national and international meetings and is/was coordinator of international uro-oncology trials.

See COI

Disease area: Bladder cancer

Biography:
Maria De Santis is a medical oncologist and has recently been appointed Chair of Section for Interdisciplinary Genitourinary Cancer Medicine at the Charité University Hospital, Berlin, Germany. Dr De Santis has been an Adjunct Professor for Oncology at the Department of Urology, Medical University of Vienna, Austria since 2016. Dr De Santis is a member of several international scientific committees, including the European Society of Medical Oncology, the European Association of Urology, and the German Society for Hematology and Oncology. She also served as a scientific committee member of the American Society of Clinical Oncology for a 3 year term. She has authored multiple peer-reviewed articles in genito-urinary cancer medicine. In addition, Dr De Santis is a panel member of the European Association of Urology Scientific Office and Guidelines Board and the International Consultation on Urologic Diseases guideline groups on bladder, testicular and prostate cancer. Her research interests include prostate, bladder, renal and testicular cancer.

See COI

Disease area: Renal Cell Carcinoma

Biography:
Guillermo de Velasco, MD PhD is a medical oncologist with special interest in genitourinary (GU) tumors. Dr. de Velasco received his medical degree from Complutense University, Madrid, Spain in 2006. In 2011, Dr. de Velasco completed his residency training in Medical Oncology at the University Hospital 12 de Octubre in Madrid, Spain. During the last two years of his fellowship, he also obtained a Master’s degree in Molecular Oncology at the Spanish National Cancer Research Center (CNIO) in Madrid, Spain. After finishing his Oncology fellowship in Spain, Dr. de Velasco was awarded with an ESMO fellowship to work in the Genitourinary Department at Cambridge University, UK under the directorship of Professor Tim Eisen. While there, he also developed research in Christian Frezza’s Lab to explore metabolomics signatures in kidney cancer. In 2015, Dr. de Velasco was awarded with a SEOM fellowship to join the Dana-Farber/Harvard Cancer Center in Boston, MA, USA, as a research fellow with Professor Toni K. Choueiri, where he was involved in several clinical and translation investigations in the GU field. Dr. de Velasco is currently an independent clinical researcher and attending physician at University Hospital 12 de Octubre. His research focuses on understanding mechanism of response and resistance to different treatments in in renal cell carcinoma and other GU malignancies.

See COI

Disease area: Bladder cancer

Biography:
Prof. Dr. Karel Decaestecker is Head of Clinic at the department of Urology at Ghent University Hospital, Belgium. He graduated magna cum laude as Master in Medicine in 2006 and completed his residency in Urology in 2012 at Ghent University Hospital. In 2012, he became Fellow of the European Board of Urology with the second highest score. On September 11th, 2015, he succesfully defended his Ph.D. on Metastasis-directed therapy for oligometastatic prostate cancer recurrence at Ghent University and is appointed as Professor Uro-Oncology at Ghent University since October 1st, 2018. He had his training in robotic surgery in 2011 in AZ Groeninge Kortrijk and OLV Aalst, Belgium. He has performed over 500 robotic procedures, mainly in the field of uro-oncology. He was trained by Prof. Dr. Abolfazl Hosseini (Karolinska University Hospital, Stockholm, Sweden) in robotic cystectomy and totally intracorporeal urinary diversion and has performed > 200 procedures, including 100 intracorporeal neobladder reconstructions. He performed the first robot-assisted kidney transplantation in Belgium in april 2016 after training at ORSI academy by Prof. Dr. Rajesh Ahlawat (New Dehli, India) and Dr. Alberto Breda (Fundacion Puigvert, Barcelona). He also performed the first European robot-assisted kidney autotransplantation in june 2017. Dr. Decaestecker is an active member of several scientific parties, including the EAU Robotic Urology Section (ERUS) Robot-assisted Kidney Transplantation (RAKT) group and the ERUS Scientific Working Group Bladder Cancer. He has recently joined the EAU Section of Transplantation Urology (ESTU) board. He is also in the Board of Directors of the BVU Scientific Summits. Dr. Decaestecker has written or colaborated in several scientific papers, mainly in the field of uro-oncology, kidney transplantation and minimal invasive surgery. He is highly involved in teaching and training medical students, residents and fellow urologists/surgeons.

See COI

Disease area: Breast cancer

Biography:
Dr Antoine Desmet has been working as a Radiation Oncologist at the Jules Bordet Institute, Brussels, Belgium since 2018. After graduating from the Catholic University of Louvain (UCL), Brussels, in 2012, he completed his residency in Radiotherapy-Oncology at Jules Bordet Institute. In 2018, he obtained his Master of Specialization in Radiotherapy-Oncology with greatest distinction (summa cum laude) and was nominated for the Dean’s Award (Université Libre de Bruxelles (ULB)). During his residency, he received training by ABRO/BeSTRO (Belgian Society of Radiation-Oncology) and completed a post-graduate training in Radioprotection. He is member of the Belgian Society of Radiation Oncology (BVRO), the European Society for Radiotherapy and Oncology (ESTRO) and lecturer at the Université Libre de Bruxelles (ULB) at the Faculty of Medicine. Dr Desmet is highly involved in teaching and training medical students and residents. He is the Radiation Oncologist in charge of the breast clinic at Jules Bordet Institute and is specialized in breast cancer, skin cancer and Intra Operative Radiotherapy (IORT).

See COI

Disease area: Breast cancer

Biography:
Véronique Diéras, MD, is senior medical oncologist and head of the Breast Cancer Group in the Department of Medical Oncology at the Centre Eugène Marquis in Rennes, France and former Head of Clinical Research, Department of Medical Oncology in Institut Curie, Paris, France Dr Diéras received her medical training at the University of Nantes, France, and completed residencies and further specialty training at the Hospital of Rennes and at the Institut Curie. She also earned a master’s degree in human biology at the University of Paris Saint Antoine and in oncopharmacology at the University of Paris Saint Louis-Lariboisière. She was visiting Professor at the Institute for Drug Development in San Antonio, Texas (Prof Von Hoff). Her main focus is breast cancer treatment and research and early drug development. Dr Diéras is involved in early clinical trials, breast cancer trials, and a translational research program focusing primarily on predictive factors of response to treatment. She is principal investigator in several national and international studies of breast and other cancers in adjuvant treatment and metastatic disease. Dr Diéras is a member of several societies, including the European Society of Medical Oncology (ESMO; Scientific Committee and track chair Metastatic Breast Cancer 2020), American Society of Clinical Oncology (ASCO), European Organisation for Research and Treatment of Cancer (EORTC, former member of the EORTC’s New Drug Development Program, Drug Study Group in Oncology, and Breast Group, Protocol Review Committee), the French Drug Agency, Institut National du Cancer, and UNICANCER (Breast Board, Early Clinical trials, Personalized Medicine, and former chair of the Early Clinical Trials Group). She is a participant in the European School of Oncology. Dr Diéras serves on the editorial board of Lettre du Cancérologue and as a reviewer for various oncology journals. She is author or co-author of more than 200 publications in such journals as Journal of Clinical Oncology, New England Journal of Medicine, Annals of Oncology, The Lancet Oncology, Clinical Cancer Research, Cancer Chemotherapy and Pharmacology, the British Journal of Cancer, and International Journal of Cancer.

See COI

Disease area: Prostate cancer, Bladder cancer

Biography:
Dr. José Luís Domínguez-Escrig graduated in Medicine and Surgery in July1994, in Valencia, Spain, continuing his postgraduate training in the UK. Having completed his BST obtained the Membership of the Royal College of Surgeons of England in 2001 and the Fellowship of the Royal College of Surgeons in Urology, FRSC(Urol) in 2009. From 2004 to 2006 he performed his research at the prestigious Northern Institute for Cancer Research-Newcastle University, UK. On completion of his research project, he submitted the Thesis “Tyrosine Kinase and Farnesyltarnsferase Inhibitors: Potential Selective Tailored Therapeutics in Bladder Cancer” and was awarded the Degree of Doctor of Medicine in 2006. He has published in several international peer reviewed Journals and he has reviewed articles for BJU Int, Urol Oncology and the Journal of Urology and has imparted several lectures and presented at international meetings including AACR, AUA, EAU, BAUS and AEU. He returned to Spain in 2011 and he is currently working as a Consultant Urology Surgeon at the Fundación Instituto Valenciano de Oncología (I.V.O.) in Valencia, where he combines his clinical work with an active involvement in translational research, participating as PI in several Clinical Trials in prostate and bladder cancer. Since 2015 is a systematic reviewer for the EAU NMIBC Guidelines panel and also Spanish delegate to the European Board of Urology (E.B.U.) as well as, member of the F.E.B.U. examination committee. His main interests are urothelial carcinoma NMIBC and MIBC and the evaluation and development of focal therapies in Uro-oncology.

See COI

Disease area: Prostate cancer

Biography:
Tanya Barauskas Dorff, M.D., is an associate professor in the Department of Medical Oncology & Therapeutics Research and serves as head of the genitourinary cancers program at City of Hope Comprehensive Cancer Center, Duarte, CA, USA. She is an internationally recognized leader in prostate cancer, serving on the NCCN guidelines panel for prostate cancer as well as being co-chair of the SWOG Prostate Cancer committee. After graduating from UCLA medical school and residency at Mount Sinai, she completed her hematology-oncology fellowship training at LAC-USC Medical Center, later serving as faculty at the USC Norris Comprehensive Cancer Center prior to joining City of Hope. Dr. Dorff’s research interests in prostate cancer are focused on novel immunotherapy and immunomodulatory strategies. With the support of the Prostate Cancer Foundation she is leading a trial of a novel PSCA targeted chimeric antigen receptor (CAR) T-cell developed at City of Hope, and is working with Dr. Priceman and the Specialized Programs of Research Excellence (SPORE) with UCLA to further advance this powerful technology for the treatment of prostate cancer. She also has federal and foundation funding for projects studying early PARP inhibition in diverse prostate cancer patients, ctDNA as a tool in understanding cancer evolution, and development of a novel radiopharmaceutical. Dr. Dorff has published over 90 original research manuscripts along with more than 50 review articles and editorials in top-tier journals, including Cancer, Lancet Oncology and Journal of Clinical Oncology. She is currently associate editor for the journal Prostate Cancer Prostatic Diseases as well as Seminars in Urologic Oncology, and acts as a reviewer for a dozen other journals. She serves a key role in several multi-center trials of immunotherapy including other CAR-T constructs and T-cell engaging antibodies. She has been invited to speak at multiple national and international meetings about her research.

Disease area: Bladder cancer, Renal Cell Carcinoma

Biography:
Ignacio Durán is a medical oncologist with interests in clinical and translational research and medical education. He is the Coordinator of the Genitourinary Oncology Program at the Medical Oncology Department in Hospital Universitario Marques de Valdecilla,Santander, Spain. Dr Durán earned his medical degree in 1997 at the Universidad de Salamanca, Spain, and went on to attain his doctorate in 2005 at the Universidad Complutense, Spain, with highest commendation. Between 2004 and 2007, he completed a fellowship in drug development and genitourinary tumours at the Princess Margaret Cancer Centre in Toronto, Canada, and a master’s degree in the teaching of medicine at the University of Toronto. Dr Durán is a member of the American Society of Clinical Oncology, the European Society of Medical Oncology, and the Spanish Society of Medical Oncology. His major research interests include genitourinary tumours and anticancer clinical drug development. He has authored numerous publications covering diverse areas of medical oncology in peer-reviewed scientific journals. Throughout his career, Dr Durán is recipient of the ASCO Foundation Merit Award, the Novartis Young Canadian Investigator Award, and the University Health Network Outstanding Research Presentation Award.

See COI

Disease area: Prostate cancer

Biography:
James A. Eastham, MD, is a surgical oncologist who completed his fellowship in urologic oncology in 1995 and has been in practice since then, devoting the past 20 years exclusively to the care of men with prostate cancer. He currently is Chief of the Urology Service in the Department of Surgery at Memorial Sloan Kettering (MSK) Cancer Center, Director of Clinical Research for the Urology Service, and Co-Leader of the Genitourinary Disease Management Team at MSK, New York, NY, USA. Dr. Eastham holds the Peter T. Scardino Chair in Oncology at MSK. He is also a professor of urology at Weill Cornell Medical College in New York, NY, USA, where he has been a member of the faculty since 2001. In 2017 he was named an honorary professor at Macquarie University, Macquarie Park, NSW, Australia. He is a member of the Prostate Cancer Guidelines Committee of the National Comprehensive Cancer Network (NCCN), President-elect of the New York Section of the American Urological Association (AUA), and a member of the Board of Governors of the American College of Surgeons (AUA representative). Dr. Eastham’s primary research interests are in improving outcomes (such as cancer control, urinary continence, and sexual function) following surgery for prostate cancer and in clinical correlations and biomarker analysis of prostate cancer.

See COI

Disease area: Bladder cancer

Biography:
Dr. Eckstein studied medicine at the Friedrich-Alexander University’s Medical School in Erlangen, graduated in 2015 and received his doctoral degree in 2016. Since 2023 he is senior consultant in surgical and molecular pathology at the Institute of Pathology of FAU Medical School (Director: Prof. Arndt Hartmann) where he serves in diagnostic services, supervises the routine histology laboratory and the clinical trial unit. He furthermore runs a translational research laboratory focusing on uropathology and immune oncology. He is member of the Germany Society of Pathology, the International Academy of Pathology (German Section) and the European Society of Urology (EAU) where he serves as volunteer in the EAU PI network and the ESUP. His main research focus lies on characterization of immune phenotypes, immune evasion mechanisms and the crucial role of immune checkpoint proteins in muscle-invasive bladder cancer. As a result of his scientific work he authored and co-authored more than 150 peer-reviewed PubMed list scientific articles.

See COI

Disease area: Prostate cancer

Biography:
Jason A. Efstathiou, MD, DPhil, FASTRO, FACRO is Professor of Radiation Oncology at Harvard Medical School (HMS), Vice-Chair for Faculty & Academic Affairs and Director of the Genitourinary (GU) Division in the Department of Radiation Oncology, and Clinical Co-Director of The Claire and John Bertucci Center for GU Cancers at the Massachusetts General Hospital Boston, MA, USA. He is an internationally recognized leader in the field of GU malignancies and Radiation Oncology. His research has informed clinical guidelines and made novel contributions to organ preservation therapy for bladder cancer, technology assessment of proton beam therapy for prostate cancer, as well as global oncology outreach efforts. He is the recipient of significant grant funding and serves as the Principal Investigator or Co-Chair of multiple multi-center, NCI-sponsored, randomized trials in bladder and prostate cancer. Dr. Efstathiou holds multiple leadership and Board positions within professional societies (ASTRO, ASCO, ABR, ACRO, ROI), patient advocacy organizations (BCAN, MPCC), within the NCI where he previously served as Co-Chair of the Bladder Cancer Task Force, and within NRG Oncology where he is the Vice-Chair of the GU Steering Committee and Bladder Lead. Dr. Efstathiou is the current Past-Chair of the Genitourinary Cancers Symposium (GU ASCO). In addition, he has a strong proven track record in teaching and mentorship and was recently awarded the A. Clifford Barger Excellence in Mentoring Award from HMS. Dr. Efstathiou holds a B.S. from Yale University, M.D. from HMS, D.Phil. from the University of Oxford, and completed his residency training in the Harvard Radiation Oncology Program.

See COI

Disease area: Breast cancer

Biography:
Dr. Alexandru Eniu is a senior medical oncologist at the Hôpital Riviera-Chablais, Vaud-Valais, Switzerland, where he took a position in January 2020 as Breast Unit Responsible and Disease Lead for Breast Cancer. He previously worked in the Department of Breast Tumours at the Cancer Institute "Ion Chiricuta" in Cluj-Napoca, Romania. He holds an MD and PhD degree in Medical Sciences, both from the University of Medicine “Iuliu Hatieganu” in Cluj-Napoca. Dr. Eniu has gained extensive experience from visits abroad. He was awarded a Mayo Foundation Visiting Clinician Scholarship at the Mayo Breast Cancer Clinic in Jacksonville, Florida and has been a visiting clinician at the MD Anderson Cancer Center in Houston, Texas and the Memorial Sloan Kettering Cancer Center in New York. He did a fellowship at the European Institute of Oncology in Milan, Italy. As an active member of both national and international societies, Alexandru Eniu holds positions in various committees. In 2018, he was appointed Deputy Scientific Director of the European School of Oncology after serving for several years as coordinator for the ESO Eastern Europe and Balkan Region Program. Within ESMO, he chaired the ESMO Global Policy Committee, and between 2014-2018 he was a member of the ESMO Executive Board, leading several initiatives tackling disparities in cancer outcomes across Europe and the world. Within ASCO, he served as chairman of the ASCO International Affairs Committee. Furthermore, he is a member of the editorial board of several oncology journals, including Annals of Oncology. He participated in the process of developing international and national guidelines for the management of cancer patients, serving as the Co-Chair of the Treatment and Allocation of resources Panel of the Breast Health Global Initiative and as panel member of the Advanced Breast Cancer (ABC3 and ABC4) International Consensus Conference. Dr. Eniu wrote 6 book chapters and more than 80 articles in international peer-reviewed journals within his specialty of breast cancer.

See COI

Disease area: Prostate cancer, Bladder cancer

Biography:
Dr Valérie Fonteyne is a staff member of the Department of Radiotherapy-Oncology at the Ghent University Hospital, Ghent, Belgium since 2003. Her research interests include urological tumours, pain management and stereotactic body radiation therapy. Dr Fonteyne graduated in Medicine at the Ghent University Hospital in 2003. She received training in Radiotherapy-Oncology until 2010. She completed a post-graduate training in Radioprotection in 2003 and in Biostatistics in 2006. In 2010, she obtained her PhD which was entitled ‘Intensity-modulated radiotherapy and arc therapy for prostate cancer: clinical results and new perspectives’. She is member of the Belgian Society of Radiation Oncology (BVRO), the European Society for Radiotherapy and Oncology (ESTRO) and the European Association of Urology (EAU). She is teacher of the ESTRO Prostate course. Dr Fonteyne (co-)authored more than 85 publications and was co-author of 2 book chapters. She participated in ‘Silico clinical trial in lung, prostate and head cancer, comparing photons, protons and C-ion therapy treatment: a multicentre planning study based on a reference dataset of patients’.

See COI

Disease area: Breast cancer

Biography:
Pierfrancesco Franco is currently Associate Professor at the Department of Translational Medicine, University of Eastern Piedmont and Clinical Consultant at University Hospital 'Maggiore della Carita', Novara, Italy. Pierfrancesco works on research in Radiation Oncology, focusing on breast cancer, gastrointestinal malignancies, head and neck. He is involved in cancer education and interested in research on professional well-being in oncology.

See COI

Disease area: Breast cancer

Biography:
Dorota Gabryś is a Radiation Oncologist working at Maria Sklodowska-Curie National Research Institute of Oncology (MSCNRIO) in Gliwice, Poland as an Assistant Professor. She obtained her MSc in Radiation Biology at University College London, UK, before earning her MD and PhD in Radiation Oncology. She performed research as part of the Tumour Microcirculation Group at the Gray Cancer Institute in London, UK, at the Technical University of Dresden Medical School, and the PET Center Dresden-Rossendorf at the Research Center Dresden-Rossendorf, Germany. Her research programme as a Radiation Oncologist is dedicated to providing the best breast cancer radiotherapy in patients treated in postoperative settings as well as in advanced inoperable cases with and without hyperthermia. She also performed investigations into the radiation-induced heart disease in breast cancer patients as well as in animal studies. Moreover, her research interest is in improving outcomes for patients with metastatic disease treated with stereotactic cranial and extracranial radiotherapy using CyberKnife, Edge, TrueBeam and tomotherapy. She likes difficult cases, and is therefore engaged in re-irradiation and multiple re-irradiation in variable localisations. Dr. Gabryś is a member of the Clinical Committee of the European Society for Therapeutic Radiation Oncology (ESTRO), as well as the Polish societies PTO, PTRO, PTBR.

See COI

Disease area: Prostate cancer

Biography:
Giorgio Gandaglia is a Urologist at the Department of Urology, San Raffaele Hospital, Milan, Italy. He earned his MD in 2011 at the Vita-Salute University, Milan where he also pursued residency. He completed a Research Fellowship in Urologic Oncology at the Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada under the supervision of Prof. Pierre I. Karakiewicz and a fellowship at the OLV Robotic Surgery Institute, Aalst, Belgium, under the supervision of Prof. Alexandre Mottrie. Dr. Gandaglia has written and coauthored more than 220 peer-reviewed journal articles (PubMed) and his H-Index is 27 (Scopus). He serves as Reviewer for the main urologic journals and in the year 2015 he was selected as Reviewer of the Year by European Urology. Dr. Gandaglia is a member of the EAU Young Academic Urologists Working Party – Prostate Cancer since March 2016. Moreover, Dr. Gandaglia is a member of the Scientific Committee of the Italian Society of Urology (SIU). His main clinical and research interests are focused on prostate cancer, benign prostatic enlargement and bladder cancer with a particular focus on minimally invasive techniques and robotic surgery.

See COI

Disease area: Breast cancer

Biography:
Joseph Gligorov is Professor of Medical Oncology at the University of the Sorbonne and Medical Practitioner in the Department of Medical Oncology at Tenon Hospital (AP-HP), Paris, France. He is currently the executive director of the University Institute of Cancer (AP-HP) Sorbonne University, grouping treatment, education and research on cancer within a network of 7 university hospitals and the different departments of Sorbonne University (Sciences and Humanities). This structure takes care of more than 15,000 cancer patients each year (including more than 10,000 newly diagnosed per year) in all areas of hematology and oncology and at all ages from pediatrics to geriatrics. Regarding his clinical activity, he is co-chairing the Breast Cancer Expert Center at Tenon Hospital and is mainly involved in breast cancer treatment. His clinical and translational research activity is focused on breast cancer predictive and prognostic markers. He is involved in clinical research and he is member of several steering committees and independent data monitoring committees (IDMC). He is also part of the INSERM U938 team “Cancer biology and treatments”, mainly involved in the field of breast cancer and its endocrine dependence. Joseph Gligorov is vice-president of the French National College of Cancerology Education and his educational activity is focused primarily on student and resident oncology education. At Sorbonne University, he is developing new educational programs for specialized nurses in oncology and for patients in partnership with the “patient’s university”. Prof Joseph Gligorov is in charge of the Nice – Saint-Paul-de-Vence breast cancer conference and treatment guidelines, and is a member of different national working groups devoted to cancer treatment strategies. He is also co-founder and president of the Mediterranean Association for Radiotherapy Oncology and Medical Oncology (AROMe) devoted to cancer patients care improvement, access to innovations and oncology education in emerging countries around the Mediterranean area. He is a member of several editorial boards, advisory committees and national and international scientific societies. He is also an ESMO and ESO core faculty member and is one of the members of the ESO-ESMO Metastatic Breast Cancer Task Force. Joseph Gligorov has published more than 300 journal articles (among them more than half Medline indexed) and participated in the editing and writing of several books.

See COI

Disease area: Breast cancer

Biography:
Dr Michael Gnant is Full Professor of Surgery at the Medical University of Vienna, Austria, where he also serves as President of the Austrian Breast & Colorectal Cancer Study Group. He is co-chairing and hosting the renowned St Gallen International Consensus Panel for Early Breast Cancer in Vienna since 2015. Dr Gnant graduated in medicine in Vienna (1988) and subsequently specialized in surgery (1994) and surgical oncology. He also worked as a Visiting Scientist at the National Cancer Institute, National Institutes of Health, Bethesda, USA (1997–1999). Dr Gnant’s research interests include several fields of surgical oncology, in particular breast and pancreatic cancer, immunotherapy, bone-targeted treatment for tumour micrometastases, tumor dormancy/quiescence and late relapse, pathway-directed therapies such as mTOR and CDK4/6 inhibition, SERDs, and he has been the Principal Investigator of many (N>30) clinical trials in these fields. The author of more than 550 original peer-reviewed papers with an impact factor of 4,800 and an h-index of 90, Dr Gnant has presented over 1,000 lectures at national and international meetings. He is the recipient of multiple awards including the prestigious Claudia von Schilling Prize from the Medical University of Hannover, the Umberto Veronesi Lecture Award of Breast Surgery International, and a Corresponding Member of the Austrian Academy of Sciences. He holds an honorary MD degree of Sichuan University, Chengdu, China, and an Honorary Professorship of Tianjin University, China. In 2017, 2021, and 2022, he was among the most highly cited scientists worldwide. Dr Gnant is involved in many scientific societies including ASCO, AACR, ACS, Breast International Group (BIG), EORTC, ESSO, EUSOMA and UICC. He served as an executive board member of BIG, is an independent reviewer and IDMC member for the EORTC, UICC and other international bodies, and is a scientific reviewer and process evaluator for the European Union. Dr Gnant is also Editor-in-Chief of BREAST CARE, and editorial board member and reviewer for many top-tier peer-reviewed journals including The Lancet, The New England Journal of Medicine, Journal of Clinical Oncology, and Annals of Oncology.

See COI

Disease area: Prostate cancer, Bladder cancer

Biography:
Prof. Juan Gómez Rivas is a urologist at the Hospital Clínico San Carlos in Madrid, Spain and associate professor at the Complutense University of Madrid. He received his medical degree in 2007, and his PhD in 2017. He has an extensive specialised training, including a master's degree in Comprehensive Medical and Surgical Management of Localised, Advanced and Metastatic Kidney Cancer and Prostate Cancer. His healthcare activity is focused on the field of genitourinary tumours, from localised disease to advanced stages, covering both medical and surgical management in its different approaches (open, minimally invasive, robotic, focal) of prostate, kidney and bladder cancer, among others. He is speaker and director of numerous courses at national and European level. Prof. Juan Gómez Rivas is active in several scientific societies such as: chair of the Young Academics Urologist (YAU) of the European Association of Urology (EAU), member of the Board of the Young Urologist Office (YUO-EAU), member of the Board of the European School of Urology (ESU-EAU), member of the Board of the European Section of Onco-Urology (ESOU-EAU), associate member of the European Section of Uro-Technology (ESUT-EAU), director of the Education Office of the Spanish Association of Urology (AEU) and member of the Spanish Society of Surgical Research (SEIQ). He participates in research as a member of the Health Research Institute of the Hospital Clínico San Carlos (IdISSC) in the area of clinical and translational research in oncology. Finally, Prof. Gómez Rivas' extensive curriculum is completed with the authorship and collaboration in more than 300 scientific publications, special editions, book chapters and has numerous participations in national and international meetings and congresses.

See COI

Disease area: Prostate cancer, Renal Cell Carcinoma

Biography:
Francisco Gómez-Veiga studied Medicine at the University of Santiago de Compostela, Spain, where he obtained his Degree in Medicine. During 1987-1992, he received his internship training in Urology at the A Coruña University Hospital, where he obtained his PhD degree. His main activities were focussed on kidney transplant and uro-oncology. Currently, he is Head of the Urology Department and Kidney Transplant, Head of the Grupo de Investigación Traslacional de Urología (GITUR) and Professor of Medicine at the University Hospital of Salamanca, Spain. He received training in several European and US hospitals on different techniques and aspects of kidney transplant and oncology. Francisco Gómez-Veiga has been coordinator and member of the steering committee in different clinical trials (CT). He has wide experience in more than 50 CT, mainly focussing on uro-oncology. Nowadays, he is the main investigator in 20 ongoing Phase II-III CT on prostate cancer, from local to castrate-resistant prostate cancer, bladder cancer, kidney tumours and benign prostatic hyperplasia. His team is also running different lines on basic research of prostate and bladder cancer. He is co-author of more than 120 published national and international articles and 30 published books related to kidney transplant and uro-oncology. He is a peer reviewer for urological journals such as Actas Españolas de Urología, Archivos Españoles de Urología, Urology International, Canadian Urological Association Journal and European Urology Supplements, and is an active member of the Scientific Committee of Spanish Guidelines for Prostate Cancer, the Spanish Urological Association (AEU), the European Board Urology (EBU sub-specialty), the Scientific Committee of the European Urological Association (EAU), the American Urological Association (AUA), the Genito Urinary Cancer Group “EORTC” and is international reviewer for the French National Cancer Institute. He received awards from the Spanish and European Urological Associations and Société Internationale d´Urologie in recognition for outstanding publications and presentations.

See COI

Disease area: Prostate cancer, Bladder cancer

Biography:
Paolo Gontero is Associate Professor of Urology at the University of Studies of Torino, Division of Urology, San Giovanni Battista Hospital, Torino, Italy. He is currently Director of a Second Level Master Degree Course in Prostate Oncology at the University of Torino. His main clinical interests are Oncology Urology Surgery, Laparoscopic and Robotic kidney and prostate oncological surgery and Reconstructive Urology. He has authored and co-authored more than 150 publications on international journals. His main research interests pertains the development of new treatment modalities for non-muscle invasive bladder cancer and prostate cancer. He is Scientific Director of the “Torino Prostate Project”, a multidisciplinary clinical and research working group in the field of prostate cancer. He is involved in international trials and working groups on the development of new diagnostic and therapeutic modalities for prostate cancer and on the assessment of surgery in high risk prostate cancer. He is chairmen of the Course on Small Renal Masses at the European School of Urology and holds active membership with EORTC-GU, ISSECAM-EMPACT and eGUS. He has co-authored several book chapters and edited several books, including the latest Problem Based Urology, Springer 2013, awarded by the BMA Book Award as highly commended n surgical specialties.

See COI

Disease area: Breast cancer

Biography:
Helena S. Gouveia is a young Breast Medical Oncologist working at the Breast Unit of the Champalimaud Centre for the Unkown in Lisbon, Portugal for the last 3 years. Participating in both translational and clinical research, she is keen on survivorship issues which commonly affect breast cancer patients. She strives to practice evidence-based medicine, ensuring all patients reach the best possible care. As a member of ESMO, ASCO and other research societies alike, she values continuous learning and helping her peers achieve optimal care for breast cancer patients worldwide, by following and adapting existing oncology guidelines.

See COI

Disease area: Prostate cancer

Biography:
After graduating from Medical School in 1998, Alexander Govorov started his residency in Urology at the Department of Urology of MSMSU in Russia. In 2001 he did a Clinical Fellowship with Prof. L. Boccon-Gibod at the Department of Urology of the Bichat Hospital in Paris. In 2002 he obtained his PhD from MSMSU. He accepted a position of Associate Professor of Urology at the Urology Department of the Moscow State University of Medicine and Dentistry (Chairman - Prof. D. Pushkar) in 2003, and became Professor of Urology in 2017. He is board certified for Urology and Oncology. Dr. Govorov is a member of the EAU, AUA, SIU and the Russian Associations of Urology and Oncology and was a Board Member of the European Society of Oncological Urology (ESOU) from 2006 to 2017. In 2017-2018 – EAU Prostate Cancer Guidelines panel member. In 2006 he has won the Russian award for “The valuable contribution to Russian Urology”. Alexander Govorov’s primary clinical interest concentrates on operative and conservative uro-oncology, and particulary on prostate biopsy and minimally-invasive treatment of prostate cancer. In 2003, he was the first HIFU specialist in Russia and in 2010 he performed the first cryoablation of the prostate in Russia. He has published in several medical journals, wrote chapters of books, participated in many academic and clinical trials and he presented at numerous national and international congresses. Since 2022 – Professor of Russian Academy of Sciences. Since 2023 – Head of Department of Oncological Urology, Botkin Hospital (Moscow) and ROSUNIMED.

See COI

Disease area: Bladder cancer

Biography:
Dr. Petros Grivas is a board-certified medical oncologist with expertise and experience in treating genitourinary (GU) cancers. He is the new Clinical Director of the Genitourinary Cancers Program at University of Washington and Associate Professor in the Dept. of Medicine, Division of Oncology. He is also an Associate Member in the Fred Hutchinson Cancer Research Center. He was recruited from the Cleveland Clinic, Cleveland, OH, where he was leading the bladder/urothelial cancer program, pursuing clinical and translational research, organizing community outreach events, mentoring trainees, and seeing patients with GU cancers. Dr. Grivas completed his training at the University of Patras Medical School and took his M.D. degree in 2005; he then pursued Ph.D. in Medical Oncology under the mentorship of key academic faculty and defended his thesis successfully in late 2008. He completed his Residency in Internal Medicine at Hahnemann University Hospital/Drexel University College of Medicine (Philadelphia, USA) in 2010. He then completed his Fellowship in Hematology/Oncology at University of Michigan (Ann Arbor, USA) in 2013. He stayed there as Clinical Lecturer for another year before he was recruited as Assistant Professor at the Cleveland Clinic (Cleveland, USA). He has had main role in clinical trials that led to the FDA approval of new drugs for bladder/urothelial cancer, and is considered a key opinion thought leader and international expert, giving lectures in several countries, educating oncologists, other healthcare providers and trainees, leading innovative clinical trials, reviewing grant proposals and manuscripts, and publishing novel, transformative and important research. He is dedicated to efficient, personalized and outstanding patient care and believes in optimal patient-physician relationship, mentorship and community outreach.

See COI

Disease area: Breast cancer

Biography:
Valentina Guarneri is Associate Professor of Oncology at the University of Padova and head of the Network Clinical Research Unit at the Oncology Institute Veneto in Padova, Italy, where she is Vice-Director of the Specialty Programme in Medical Oncology. From 2015 to 2018, she was member of the Research Committee of the Italian Ministry of Health. Dr. Guarneri completed her fellowship in Oncology in 2003 and obtained her PhD degree in Clinical and Experimental Oncology in 2007. In 2005, she completed a research experience at the Department of Breast Medical Oncology, MD Anderson Cancer Center in Houston, Texas, where she also was Visiting Assistant Professor in 2009. In 2005, she was appointed Assistant Professor of Oncology at the University of Modena and Reggio Emilia in Modena, Italy, where she also chaired the Breast Unit from 2011 to 2013. Dr. Guarneri is a member of the ESMO Fellowship and Award Committee and of the Oncology Pro Working Group, and was a long-standing member of the ESMO Young Oncologists Committee (YOC). She is also a founder member of the Women for Oncology Italy initiative (a national spin-off of the ESMO initiative). She is in the editorial review board of several international journals, including The Lancet Oncology, Annals of Oncology, Clinical Cancer Research, The Oncologist and Clinical Breast Cancer. Her research interest is mainly focused on clinical and translational research for breast cancer patients. She published more than 140 papers in peer-reviewed journals (JCR-ISI WEB 2018 Total Impact Factor: 840).

See COI

Disease area: Prostate cancer

Biography:
Still to be added

See COI

Disease area: Bladder cancer

Biography:
Dr Shaista Hafeez is a Clinical Oncology Consultant at The Royal Marsden NHS Foundation Trust, London, UK. Dr Hafeez graduated from Imperial College School of Medicine at St. Mary’s, London. She completed specialist clinical oncology training in London. In 2013, she was awarded a Cancer Research UK PhD Fellowship and undertook a period of research at The Institute of Cancer Research and The Royal Marsden Hospital investigating functional Magnetic Resonance Imaging (MRI) and advanced image guided adaptive radiotherapy techniques in bladder cancer. Dr Hafeez received several awards for this work including The Royal College of Radiologists Ross Award, The National Cancer Research Institute (NCRI) Prize, and in 2017 she was awarded The Chairman’s Prize, for her PhD at The Institute of Cancer Research. Dr Hafeez was appointed jointly as Consultant Clinical Oncologist and Clinician Scientist in the Urology Unit and Division of Radiotherapy and Imaging at The Royal Marsden and The Institute of Cancer Research in 2017. She specialises in radiotherapy and systemic treatment of patients with urological cancers, in particular those with bladder cancer. Her on-going research aims to improve patient outcomes by developing individualised approaches to radiotherapy delivery.

See COI

Disease area: Breast cancer

Biography:
Nadia Harbeck, MD, PhD, is head of the Breast Center and holds the chair for Conservative Oncology at the Department of OB&GYN at the University of Munich (LMU), Germany. She obtained her specialist degree (OB&GYN) at the Technical University of Munich (TUM) and her medical degree from the University of Munich. From 2005-2009, she was an assistant professor and head of Conservative Senology at TUM and from 2009-2011, she was head of the Breast Center at the University of Cologne, Germany. Professor Harbeck is a member of the expert panel issuing the yearly updated evidence based AGO Guidelines for breast cancer therapy in Germany (www.ago-online.de). She is scientific director of the West German Study Group (www.wsg-online.com). From 2009-2015, she served on the executive board of the EORTC as the chair of the translational research division. Professor Harbeck is principal investigator or steering committee member of numerous national and international clinical breast cancer trials, particularly with novel targeted compounds. Her translational research focuses on prognostic and predictive factors in breast cancer and other solid tumours. She has a strong interest in eHealth and is a co-developer of CANKADO, an international digital patient diary (www.cankado.com). Professor Harbeck has authored more than 470 papers in peer-reviewed journals (cumulative impact factor >3000; h-index 80) and is coordinating editor-in-chief of Breast Care (Karger Publishers). For her clinical translational research, she has received numerous awards, including the 2015 Bavarian Cancer Patient Award, the 2012 Claudia von Schilling Award, the 2008 EBCC Award (Emmanuel van der Schueren Lecture), the 2002 AGO Schmidt-Matthiesen Award, a 2001 AACR Award, and the 2001 ASCO Fellowship Merit Award for the highest ranking abstract submitted. She is a panel member of several international breast cancer consensus conferences, such as for advanced breast cancer (ABC), breast cancer in young women (BCY), and early breast cancer (St Gallen).

Disease area: Prostate cancer

Biography:
Karin Haustermans graduated in 1987 as Doctor in Medicine, Surgery and Obstetrics (MD) at the Catholic University of Leuven (KU Leuven) in Belgium. In 1993, she completed her training and qualification in Radiation Oncology. After a research fellowship at the Laboratory of Experimental Radiotherapy at the KU Leuven, she obtained her PhD in Medical Sciences for which she received in 1996 the ESTRO-VARIAN Clinical Research Award. Thereafter she spent four years as a staff member at the Netherlands Cancer Institute in Amsterdam. Currently, Karin Haustermans is Medical Director of Protontherapy ParTICLe and Secretary of the Leuven Cancer Institute at the University Hospital Gasthuisberg (Belgium). She is Full Professor at the KU Leuven. She is specialized in GI and GU oncology and has a part time appointment as a clinical research fellow of the Research Foundation Flanders. She is a member of several (inter)national scientific organizations. From 2006 to 2009 she held the Chair of the EORTC Radiation Oncology Group and from 2009 until 2015 she was Chair of the Quality Assurance Committee of EORTC. She is also heavily involved in the Belgian Cancer Registry as a member of the board and Chair of the Coordination Council. In 2010 she was awarded the ESTRO Breur medal in recognition of her major contribution to European Radiotherapy. From 2011 onwards she was appointed as a member of the Belgian Royal Academy of Medicine and in 2015 she became a fellow of the European Academy of Cancer Sciences. Since 2016 she is clinical editor of Radiotherapy & Oncology. Karin Haustermans has 289 peer reviewed publications (h-index: 51).

See COI

Disease area: Prostate cancer

Biography:
Elisabeth I. Heath, M.D., F.A.C.P., serves as the Associate Center Director of Translational Sciences and leads the Genitourinary Oncology Multidisciplinary Team at the Karmanos Cancer Institute, Detroit, MI, USA. She is the medical director of the Infusion Center and is director of prostate cancer research. She is an active clinical and scientific member of Karmanos and is professor of Oncology at Wayne State University School of Medicine, Detroit, MI, USA. Dr. Heath has a distinguished career as a prostate cancer researcher, serving as the Patricia C. and E. Jan Hartmann Endowed Chair for Prostate Cancer Research. Her focus is in conducting clinical and translational research trials in genitourinary oncology with critical attention to the area of health disparity, particularly with regard to the poor accrual of minority patients to prostate cancer clinical trials. She is the principal investigator of the Michigan Prostate Specialized Program of Research Excellence (SPORE) as well as for a grant of the United States Department of Defense in the nationally-recognized Prostate Clinical Trials Cancer Consortium. Dr. Heath is a member of the Prostate Cancer Foundation Research Awards Review Committees and United States Department of Defense prostate and kidney cancer study section. She has served as president for the Karmanos Cancer Institute Medical Executive Committee, has served as member of the Executive Committee of the Faculty Senate at Wayne State University School of Medicine, and is currently on the board of directors of the state-sponsored Michigan Cancer Consortium. Dr. Heath was honored with the inaugural Michigan Cancer Consortium Champion Award for 2016. In addition, Dr. Heath was also the recipient of the National Cancer Institute Clinical Investigator Team Leadership Award in 2010. She has also been awarded the Wayne State University School of Medicine College Teaching Award in 2007, 2011, 2015 and holds the Top Doc designation in Hour Magazine from 2010-2021. Dr. Heath served for 10 years as the Faculty Advisor for the Gold Humanism Honor Society and has been the recipient of the Leonard Tow 2009 Humanism in Medicine Award. She was the recipient of the Wayne State University School of Medicine Physician’s Golden Heart Award in 2011. Dr. Heath is a dedicated clinician-scientist, researcher, and teacher at Wayne State University School of Medicine. She earned her medical degree from Thomas Jefferson University in Philadelphia, PA, USA, completed her internal medicine residency at Georgetown University Hospital in Washington, DC, USA, and completed her medical oncology fellowship at Johns Hopkins School of Medicine in Baltimore, MD, USA.

See COI

Disease area: Breast cancer

Biography:
Anna Hester is a gynecologist at the Department of Obstetrics and Gynecology at the University Hospital Munich (LMU), Germany. She obtained her medical degree from the University of Wuerzburg and holds an additional Master of Science degree in experimental medicine. She obtained her specialist degree (OB&GYN) at the University of Munich (LMU). The fields of interest of Dr. Hester include conservative gyneco-oncology and especially predictive markers and the role of the immune system in breast cancer. She has (co-)authored 24 peer-reviewed publications.

See COI

Disease area: Bladder cancer

Biography:
Sebastian Hofbauer is a Urologist at the Department of Urology at the University Hospital of Berlin (Charité), Germany. After graduating from the Medical University of Vienna, Austria in 2012, he completed a Research Fellowship and started a Ph.D. program in Urologic Oncology at the Department of Urology at the Medical University of Vienna under the supervision of Prof. Tobias Klatte and Prof. Shahrokh F. Shariat, followed by a residency in 2013 at the same institution. In 2015, he moved to Berlin to continue his residency at the Department of Urology at the University Hospital Berlin. He has written and coauthored more than 30 peer-reviewed journal articles. He serves as reviewer for European Urology Focus. His main clinical and research interests are focused on prostate and bladder cancer.

See COI

Disease area: Renal Cell Carcinoma

Biography:
Milan Hora, Professor of Urology, was born in 1967 in Pilsen, Czech Republic. He has been an employee of the Department of Urology, University Hospital Pilsen and the Faculty of Medicine at Charles University since 1991, where he has been the Head of the Department since 2003. Dr Hora is board certified in Urology (1997) and Onco-urology (2016) and received his honorary degree at the Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. His professional training includes visits to international urological departments at AKH Wien, Austria; The Cleveland Clinic Foundation, Ohio, USA; Institut Mutualiste Montsouris, Paris, France; Mainz, Germany; Wales, Cardiff, UK, and the General University Teaching Hospital, Prague, Czech Republic. His topics of interest are mainly focussed on onco-urology (especially renal tumours and penile cancer), laparoscopy, robotic surgery and andrology. Dr Hora is vice-chairman of the Czech Urological Society, chairman of the Accreditation committee of Czech Health Ministry for Urology and Onco-urology, secretary of the Local Ethical Committee of University Hospital in Pilsen, part of the working group on Kidney Cancer of the European Association of Urology (EAU) Guidelines Office, and member of the European Board of Urology (EBU). He is editor-in-chief of the Czech Urology journal and member of the editorial board of the World Journal of Urology. In addition, he is member of the European Urology Residents Education Programme (EUREP) faculty. Milan Hora has (co-)authored 4 textbooks, 6 textbook chapters, 344 peer-reviewed publications and numerous abstracts and presentations.

See COI

Disease area: Bladder cancer

Biography:
Jacques Irani studied medicine and received his PhD in clinical epidemiology and statistics. He qualified in Urological Oncology at Poitiers University Hospital. Currently, he is Professor at Paris-Sud University and head of the department of Urology at Bicetre University Hospital. His main research interests are uro-oncology. Prof. Irani is member of several national and international associations and societies. He held the posts of chairman of the French Bladder Uro-Oncological committee (CC-AFU) and member of the British Journal of Urology International (BJUI) executive board committee. He was until 2015 vice-chairman of the European Association of Urology Guidelines Committee Board. Prof. Irani is also member of several Editorial boards, including European Urology. He published over 250 publications in both national and international journals.

See COI

Disease area: Bladder cancer

Biography:
Rob is Professor of Clinical Cancer Research at the University of Glasgow and a consultant at the Beatson West of Scotland Cancer Centre. His clinical practice is the medical management of cancers of the prostate, bladder and kidney. His research commitments include the management of a large portfolio of phase I, II and III trials. He is vice-chair of the UK National Cancer Research Institute Bladder and Kidney Clinical Studies Group (CSG), he also chairs the Advanced Disease Subgroup of the Prostate Cancer CSG. He is director of the CR-UK Clinical Trials Unit in Glasgow.

See COI

Disease area: Breast cancer

Biography:
Dr. Kaidar-Person is an associate professor at Tel Aviv University and the director of the Breast Cancer Radiation Oncology Unit at Sheba Medical Center, Ramat Gan, Israel. She is active in numerous professional societies, and a member of the steering committee of EORTC - Breast Cancer Group (BCG). She is part of the European Society for Radiotherapy & Oncology (ESTRO) breast cancer faculty, a member of ESTRO’s breast cancer focus group and guidelines group. She is currently working on her PhD project at Maastricht University, the Netherlands, focusing on postmastectomy chest wall recurrences to improve postmastectomy radiation therapy mainly after breast reconstruction. She (co-)authored more than 150 publications and book chapters and co-edited 3 radiation books. She is involved in the Cinderella trial supported by HORIZON-RIA (Proposal number 101057389) and the BRILLIANT study supported by ASCO-ICRF.

See COI

Disease area: Bladder cancer

Biography:
Prof. Ashish M. Kamat is Professor of Urologic Oncology and Cancer Research at M.D. Anderson Cancer Center; Associate Head of the Cancer Center, Reliance Foundation Hospital in Mumbai, and President of the International Bladder Cancer Group (IBCG). He is Associate Editor for European Urology Oncology, served as the Director of the MD Anderson Urologic Oncology Fellowship from 2005-2016 and is a graduate of the AUA Leadership Program. Prof. Kamat’s focus in urologic oncology is on bladder cancer, especially immunotherapy and organ sparing therapies, and he maintains an active research portfolio in this area. His research laboratory focuses on identifying and developing predictive markers of response to therapy, and research into mechanisms of inducible cancer stem cells. These findings have been published in high impact journals and he has over 275 publications to his credit. In addition, Prof. Kamat has won the ‘Compassionate Doctor Award’ from patient groups.

See COI

Disease area: Prostate cancer

Biography:
Dr. Karnes is currently the Dr Anson L. Clark Professor of Urology at the Mayo Clinic College of Medicine, Rochester, MN, USA. He received his Bachelor of Arts (BA) in Political Science at Brown University in Providence, RI, USA, and his Medical Degree (MD) with honors at Southern Illinois University School of Medicine in Springfield, IL, USA. He served an internship in general surgery and post-graduate training in urology at the Mayo Clinic, Rochester, MN, USA. Dr. Karnes’ interests include: recurrent and advanced urologic cancers; and has funded research in prostate and bladder biomarkers. He is currently a vice-chair in the Department of Urology and director of the Radical Prostatectomy Database at the Mayo Clinic College of Medicine.

See COI

Disease area: Prostate cancer

Biography:
Vincent Khoo is a Clinical Oncologist at Royal Marsden Hospital, Honorary Consultant at St George’s Hospital and Honorary Senior Lecturer at Institute of Cancer Research, London University. He was previously Head of Department of Clinical Oncology Royal Marsden. He is Adjunct Professor, Department of Medical Imaging and Radiation, Monash University and Honorary Associate Professor, Department of Medicine, Melbourne University and Austin Health. He specialises in urological cancers with interests in systemic Clinical Trials, combination treatments, multi-modality imaging, and technical radiotherapy from stereotactic to image guided intensity modulated and adaptive radiotherapy. He has published over 200 papers. He is member of several national/international committees including UK NCRI Clinical-Translational Radiotherapy, UK NCRN Prostate, Penile, and Kidney Clinical Studies Groups, ESTRO, ECCO.

See COI

Disease area: Prostate cancer

Biography:
Dr Jon Kindblom is consultant at the Department of Oncology, Sahlgrenska University Hospital in Gothenburg, Sweden. He is also a researcher and lecturer at the Sahlgrenska Academy, Gothenburg University. Dr Kindblom obtained his medical degree in 1997 and his PhD in 2003, both from Sahlgrenska Academy, Gothenburg University. During his PhD at the Department of Endocrine Physiology, he developed and studied transgenic mouse models for studies of early prostate development and mechanisms of hyperplasia. He publishes regularly in peer-reviewed journals and is the author of two text book chapters. Dr Kindblom is a regular reviewer for international journals, among others IJROBP. His clinical practice and research interest is now focused mainly on prostate cancer, specifically optimization of radiotherapy (external and high-dose rate brachytherapy). He has been co-investigator of several phase I-III clinical trials. Dr Kindblom is secretary of the Swedish Society for Urooncology (SFUO). He is also an appointed medical expert serving under the National Board of Health and Welfare in providing national guidelines for prostate cancer care and treatment.

See COI

Disease area: Prostate cancer

Biography:
Dr. Amar U. Kishan, Associate Professor, is the Vice-Chair of Clinical and Translational Research and Chief of the Genitourinary Oncology Service for the Department of Radiation Oncology at the David Geffen School of Medicine at University of California, Los Angeles (UCLA) and the UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA. Dr. Kishan specializes in the utilization of radiation to treat genitourinary malignancies (particularly cancers of the prostate and bladder). He has an extensive research background and has published over 170 manuscripts, including lead authorship publications in Journal of the American Medical Association (JAMA), Lancet Oncology, JAMA Oncology, European Urology, Cancer Cell, and the International Journal of Radiation Oncology, Biology, and Physics. He has received extensive grant support, including funding from the United States Department of Defense, the Prostate Cancer Foundation, the American Society of Radiation Oncology, the Radiological Society of North America, the Radiation Oncology Institute, and the UCLA Jonsson Comprehensive Cancer. He runs an active clinical and translational research program and has spearheaded multiple innovative clinical trials in radiation oncology.

See COI

Disease area: Prostate cancer, Bladder cancer

Biography:
Badrinath R. Konety, MD, MBA, FACS is currently serving as the President, and Chief System Research Officer at the Allina Health Cancer Institute, Minneapolis, MI, USA. He is a Professor in the department of Urology at Rush Medical College, Chicago, IL, USA, and an Adjunct Professor of Urology at the University of Minnesota, Minneapolis, MN, USA. He has recently served as The Henry P. Russe, MD, Dean of Rush University Medical College and Senior Vice President for Clinical Affairs, Rush University System for Health. Dr. Konety was previously the Associate Dean for Innovation and Director of the Institute for Prostate and Urologic Cancers at the University of Minnesota Medical School. He had multiple leadership positions during his tenure at the University of Minnesota. He was Doughery Family Chair in Uro Oncology, Chair of the Department of Urology , Associate Director for Clinical Affairs at the Masonic Cancer Center, Chair of the Oncology Service Line Steering committee and also served as Chair of the Finance Committee, the Chief Executive Officer University of Minnesota Physicians and Chief Clinical Officer for MHealth Fairview. Dr. Konety completed his residency, Master of Business Administration (MBA), and American Foundation for Urologic Disease Research Scholar fellowship at the University of Pittsburgh, Pittsburgh, PA, USA. He completed his urologic oncology fellowship at the Memorial Sloan Kettering Cancer Center, New York, NY, USA. As accomplished clinician, researcher and scholar, Dr. Konety has authored or co-authored over 300 peer reviewed publications, numerous book chapters, edited two books and has been the Associate Editor of the Journal of Urology. He has been and is principal or co-investigator on grants funded through the US Department of Defense, National Institutes of Health (NIH), American Geriatrics Society, and Center for Disease Control. Dr. Konety’s research work has focused on both basic science as well as outcomes and health services. He has worked on developing new strategies for gene therapy for advanced prostate cancer and has been involved in preclinical studies of novel chemotherapeutic agents (lupeol). He continues to work with collaborators on new markers for aggressive prostate cancer such as ROBO1 and S100A4and has been involved in the development of new markers for bladder cancer. He has been the co-lead and co-founder of Center for Healthy African American Men through Partnerships (CHAAMPS) and is a collaborative investigator on RESTORE, a series of NIH funded studies on prostate cancer in sexual minority men. Dr. Konety is an active member of numerous professional medical societies including the American Urological Association, the American College of Surgeons, Société Internationale D’Urologie (SIU) and the American Association of Genitourinary Surgeons. He is the former President of the SIU, the Society of Academic Urology and the Minnesota Urologic Society. He has received the Jahnigen Career Development Scholar Award (American Geriatric Society), the Ferdinand Valentine fellowship (New York Academy of Medicine) the David Utz award (Minnesota Urologic Society) and the Felix Guyon Medal (SIU). He has trained and mentored scores of students, residents and fellows.

See COI

Disease area: Prostate cancer

Biography:
Bridget F. Koontz, MD is US Chief Medical Officer and Deputy Global Chief Medical Officer at GenesisCare, and Affiliate Professor at East Carolina University Brody School of Medicine, Greenville, SC, USA. Dr. Koontz trained at Harvard Medical School, Boston, MA, USA, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA, and Duke University School of Medicine, Durham, NC, USA, where she was on faculty at the Duke Cancer Institute from 2007 to 2021. She is now leading the US oncology network for GenesisCare, a leading global oncology network and research organization. Her interests are in the promotion of excellent clinical care for patients with genitourinary malignancies, and in clinical and translational research to improve both the treatment of and recovery from cancer. She has frequently been faculty at American Society for Radiation Oncology (ASTRO) meetings and at American Society for Clinical Oncology Genitourinary cancers (ASCO GU) meetings, and has published over 100 articles, chapters, and books. She also acted as an associate senior editor for International Journal of Radiation Oncology Biology Physics (2015 -2018) and as senior editor of the practical handbook Radiation Therapy Treatment Effects: An Evidence-Based Guide to Managing Toxicity (2017). Dr. Koontz’s current research is focused on improving the effectiveness of prostate cancer radiotherapy and reducing the toxicities of such care. She has conducted translational laboratory research developing models of radiation-induced pelvic toxicity, has led phase I and phase II trials in prostate cancer, and is the national principal investigator of NRG-GU011, a trial of stereotactic radiotherapy for oligometastatic prostate cancer. She continues to investigate clinical efforts to improve the quality of life of cancer survivors through technology such as eHealth apps and activity trackers. She currently represents radiation oncology as a member of the National Cancer Institute’s Genitourinary Steering Committee for National Clinical Trials Network (NCTN) trials.

See COI

Disease area: Renal Cell Carcinoma

Biography:
Dr Teele Kuusk graduated from the Medical Faculty of Tartu University, Estonia in 2009. During her medical studies she was a sub-investigator at the Clinical Research Centre, getting her first experience in clinical vaccine and other medical studies. In 2015 she completed her Urology Residency at Tartu University. During her Urology training, she was working mainly in Oulu University Hospital in Finland and in Tartu University Hospital in Estonia but also had Paediatric Urology training in Bezmialem Hospital in Istanbul, Turkey, supervised by Associate Professor Mesrur Selcuk Silay (EAU Crystal Matula Award 2018, Chair of YAU). From 2009-2015 she represented Estonian Urology residents in the European Society of Residents in Urology (ESRU), organised academic training for Estonian Urology residents and also published her first manuscript on renal tumours. From 2007, she has been actively attending local and international meetings and congresses. After her residency, she worked as a Consultant Urologist in Kanta-Häme Central Hospital in Finland. In 2016-2017 she received a prestigious clinical research fellowship by the European Urological Scholarship Programme (EUSP) at the centre of excellence Antoni van Leeuwenhoek Netherlands Cancer Institute in Amsterdam, the Netherlands, where she was supervised by renal cancer leading expert Dr Axel Bex. He is a pioneer in using sentinel lymph node technique in renal tumours for the purpose of studying lymphatic drainage, which became Dr Kuusks topic for her thesis. They have won best poster prize in 2017 for their abstract “Topographic distribution of sentinel lymph nodes in patients with renal tumours” presented at the EAU Congress 2017 held in London. They have published 6 articles on the topic in peer-reviewed Urology journals and have published 12 other articles together and with co-authors. Dr Kuusk is a co-author in the EAU learning module thromboprophylaxis section and a book chapter about sentinel lymph node biopsy in renal cancer. From 2018 she is associate member of the EAU renal cell carcinoma guidelines panel. During her career she has given 12 lectures at local meetings, 4 international congresses as an abstract presenter or a session moderator and 2 times been invited speaker at international renal cancer congresses. In January 2020 she finished her one-year fellowship at the Royal Free Hospital Renal Cancer Unit in London, UK, where she was trained in robotic, laparoscopic and open surgery in renal cancer.

See COI

Disease area: Prostate cancer

Biography:
Dr. Kuzel is the Samuel G Taylor III Professor of Oncology, and the Chief of the Division of Hematology/Oncology and Cell Therapy at Rush University, Chicago, IL, USA, since June 2016. Prior to that, Dr. Kuzel spent 26 years as a Professor of Medicine and Dermatology in the Division of Hematology/Oncology at Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. In his career, he focused on the design and execution of clinical trials with a specific focus on experimental therapeutics, especially phase I and phase II therapeutics rationally designed to exploit molecular and/or protein alterations within tumor cells and immunotherapeutic approaches/agents. Agents studied have included chemotherapy drugs, targeted agents, cytokines, vaccines, and other novel immunotherapeutics. Through 2021, he was a Co-Principal Investigator on a Specialized Program of Research Excellence (SPORE) in Prostate Cancer at Northwestern University. The project focused on immunomodulation to reverse resistance to oral novel anti-androgen therapies. At Rush University, he has developed a team focused on bioinformatics to understand tumor biology and lead to therapeutic insights. He has served on a number of National Cancer Institute (NCI) site visit teams as a reviewer for Program Projects for 1) Immunotherapy in renal cell carcinoma, 2) Melanoma with dendritic cell-based immunotherapy approaches, and 3) Cellular immunotherapy, as well as 4) NCI Community Oncology Research Program (NCOROP) centers. In addition, he participated in several National Comprehensive Cancer Network (NCCN) guidelines committees, including Kidney/Testis, Bladder and Prostate cancer at various times. He serves on multiple Data Monitoring Committees of phase II and III global check point inhibitor clinical trials.

See COI

Disease area: Breast cancer

Biography:
Fanny LE DU, MD, is senior medical oncologist in the Department of Medical Oncology at the Centre Eugène Marquis in Rennes, France. Dr Le Du received her medical training at the University of Rennes, France. She also earned a master’s degree in human biology at the University of Rennes. She was visiting research student at the MD Anderson Cancer Center, Texas (Prof Ueno). Her main focus is breast cancer treatment and research.

See COI

Disease area: Bladder cancer

Biography:
Cédric Lebâcle is a hospital practitioner urologist at Bicêtre Hospital in Paris, France. He holds a diploma of Complementary Specialized Studies in Oncology and an inter-university diploma in Genitourinary Oncology. He spent a year of research at the UCLA Institute of Urologic Oncology (Prof PANTUCK), David Geffen School of Medicine in Los Angeles, CA, USA. His main research interests are uro-oncology and in particular bladder cancer. His main clinical focus is on bladder tumors and robotic surgery, in collaboration with the Gustave Roussy Institute. Dr Lebâcle is a member of several national and international associations and societies.

See COI

Disease area: Bladder cancer, Renal Cell Carcinoma

Biography:
Annemarie Leliveld is urologist and staff member at the Department of Urology of the University Medical Center Groningen (UMCG), Groningen, the Netherlands since 2005. In addition, she is Consultant Onco-Urology at the Comprehensive Cancer Center Northern Netherlands. She finished her PhD on urothelial cell carcinoma of the bladder and the upper urinary tract in 2014. Currently, she is also preparing her PhD project on the clinical aspects of diagnosis and treatment of urothelial cell carcinoma. Annemarie Leliveld received her Medical Degree from the University of Groningen, the Netherlands in 1996, and continued her resident training in surgery and urology at the Martini Hospital and Academic Hospital of Groningen, the Netherlands. She became board-certified urologist in 2005 and she obtained the Fellow of the European Board of Urology (FEBU) certificate in 2006. She is specialized in oncology, laparoscopy and endometriosis. She is member of the Dutch Association of Urology and the European Association of Urology, and of several committees at the UMCG, including the committee on endometriosis, laparoscopic surgery, palliative care and rectal carcinoma. She is also member of the National committee on oncological urology and hereditary urological tumours. She is (co-)author of several publications in peer-reviewed journals.

See COI

Disease area: Renal Cell Carcinoma

Biography:
Börje Ljungberg is a urologist and professor of Urology at the Department of Surgical and perioperative sciences, Urology & Andrology of Umeå University Hospital in Umea, Sweden. He obtained his medical degree from the Medical School of Uppsala and Umeå in 1975, and specialised in Urology and General Surgery in 1983. He defended his PhD thesis on renal cell carcinoma tumour heterogeneity and prognosis in 1986. He is chairman of the Renal Cell Carcinoma EAU Guidelines group since 2005, chairman of the National Swedish Kidney Cancer Registry since 2003, and member of the Nordic Renal Cell Carcinoma Study Group since 2016. He was board member of the Nordic Urologic Association between 2000-2015. Dr. Ljungberg’s research interests are focussed on molecular genetics and angiogenesis in urological malignancies. More specifically, cell cycle regulation, proliferation, prognostic variables and clinical research in renal cell carcinoma. He has tutored several PhD students in these fields of research. He has (co-)authored more than 300 peer-reviewed publications.

See COI

Disease area: Bladder cancer

Biography:
Yohann Loriot is a medical oncologist, physician-scientist at the Gustave Roussy Institute, Cancer Campus of the Université Paris-Saclay in the Villejuif commune of Paris, France. Dr Loriot’s main research interest is the study of the mechanisms mediating progression to lethal disease in cancers of the bladder and prostate with a focus on the development of novel strategies and therapies targeting these conditions at the molecular level. As a member of the steering committees of several international clinical trials, Dr Loriot has published extensively in his specialised field, and has been instrumental in the development of high-impact publications supporting the approval of therapeutic agents including enzalutamide, abiraterone, and atezolizumab. He also co-led the study that led to the approval of the fibroblast growth factor receptor inhibitor erdafitinib. He is currently engaged in the development of ancillary studies to help better understand the mechanisms of action of (and resistance to) targeted therapies and checkpoint inhibitors.

See COI

Disease area: Breast cancer

Biography:
Melanie Machiels obtained her Master’s in Medicine in June 2012 at the Catholic University of Leuven, Belgium and started a combined residency/PhD employment at the Radiation Oncology department of the Amsterdam UMC in the Netherlands. Her research aimed to optimise accuracy of radiotherapy for oesophageal cancer patients and was performed under the supervision of Prof. Dr. C.R.N. Rasch and Dr. M.C.C.M. Hulshof, best known for the CROSS trial. She finished her residency and PhD research project in September 2019 and started working as a radiation oncologist at the Iridium Netwerk in Antwerp, Belgium. She is also a postdoctoral researcher at the University of Antwerp with a special emphasis on breast cancer, and the head of the scientific breast cancer research group at the Iridium Netwerk. Further, she is a member of the ESTRO, GEC-ESTRO gynaecological cancer working group, EORTC gynaecological cancer working group, EORTC breast cancer working group and Editorial Board Member of Belgian Journal of Medical Oncology.

See COI

Disease area: Prostate cancer

Biography:
Dr. Stefan Machtens is head of the department of urology and pediatric urology at Marienkrankenhaus Bergisch Gladbach, an academic teaching hospital of Cologne University. After his university education in Pecs (Hungary), Bochum and Cologne he graduated in medicine in 1994. After short-term stays in St.George Hosspital in Sydney/Australia and St.Joseph Hospital in Atlanta/USA he finished his medical education at the department of surgery at Knappschafts-Krankenhaus in Dortmund Brackel. Dr.Machtens received his urologist specialist training at Hannover Medical School under Prof. Udo Jonas. He passed his board exam in 1999. Since 2002 he worked as senior staff member at Hannover Medical School. In between 2005 to 2006 he became vice chair at the University Department at Hannover Medical School. In 2003 he received his degree as „Medical Hospital Manager“ after studies at the Fachhochschule Hannover. In 2005 he specialized in „Specialized urologic Surgery“. In 2006 he qualified with the additional qualification „Andrology“ and in 2009 in „Medical Tumor Therapy“. He is member of several national and international urological societies. Since 2007 he is member of the German S3-Guideline Panel for prostate cancer. Since 2008 he is member of the EAU/ESTRO Teaching Staff in „Prostate Brachytherapy“. He has been the Managing Editor of The World Journal of Urology in between 1999-2005. Dr. Machtens has been main investigator in multiple phase I-III uro-oncological trials. Dr. Machtens has presented more than 350 invited lectures. He has published more than 90 peer-reviewed articles as author and co-author. He has published 7 books. Dr. Machtens received six national and international scientific awards on the field of uro-oncology and urologic physiology.

See COI

Disease area: Bladder cancer

Biography:
Bernard Malavaud is Head of Urology and Chief Medical Officer at Toulouse Cancer Institute in Toulouse, France and co-director of the Sphingolipids and Cancer Research Lab at the Institute of Pharmacology and Structural Biology. After his military service as a District Medical Officer in Malawi (East Central Africa) and four years of General Surgery and Urology residency, he obtained his medical degree in 1989. He defended his PhD on tumour angiogenesis in 1997 at the French National Centre for Scientific Research in Paris, France. He was a visiting scientist for one year at the Department of Biomedical engineering of Johns Hopkins University, Baltimore, USA before returning to France for a position as professor of Urology at the University Hospital of Toulouse. Dr. Malavaud was awarded the European Association of Urology 2003 Crystal Matula Award for excellence and dedication to Academic Urology, the Best Scientific Communication EAU 2016 and is a laureate of the French Ministry of Science and Research iLab 2018 (SmartCatch). He is a fellow of the European Board of Urology, board member of the European Association of Urology (EAU) and Association of Academic European Urologists, as well as member of the European School of Urology, the European Society of Uro-Technology and the French Association of Urology (AFU). He has (co-)authored several impactful, peer-reviewed publications.

See COI

Disease area: Prostate cancer

Biography:
Dr Maldonado works as Radiation Oncologist at the Hospital Universitari de la Vall d’Hebron, Barcelona, Spain, He is a member of several national and international associations as well as board member of the G.I.C.O.R. (Spanish Group for Investigation in Radiation Oncology) He is a fellow of the Spanish School in Radiation Oncology and he has chaired several times the prostate cancer courses and genitourinary oncologic meetings. He is also a reviewer of the main Radiation Oncology journals. He is author and co-author of more than 50 papers published in peer reviewed, indexed Journals. His main clinical interest is urological oncology, where he conducted several clinical trials. He is actually focused in the high risk prostate cancer tumors and in the IGRT (Image Guided Radiation Therapy) quality programs. He is the responsible of the Urological tumors in the Radiation Oncology department.

See COI

Disease area: Breast cancer

Biography:
Christos J. Markopoulos is Professor of Surgery at the Athens University Medical School in Athens, Greece. Professor Markopoulos qualified from Athens University Medical School, Greece in 1979 and he specialized in General Surgery (1985). He received his PhD from Athens University in 1985 and holds an MPhil degree in Oncology – Breast Cancer from St. George’s Medical School, University of London, UK (1988). He specialized in breast cancer management working as Senior Registrar in surgery at the Breast Unit of St. George’s Hospital and Medical School and at The Royal Marsden Hospital in London, UK (1985-1988). He has also worked as research fellow at the Ludwig Institute for Cancer Research at Sutton, Surrey, UK (1986-1987). Professor Markopoulos is the current President of the UEMS – Division of Breast Surgery and head of the examination board of the EBSQ in Breast Surgery exams (2016-2024). He has been an elected member of the European Society of Breast Cancer Specialists (EUSOMA) Executive Committee (2010-2016) and he is a member of several medical associations and societies including the UK Association of Breast Surgery (ABS), American College of Breast Surgeons (ACBS) and the European Society of Surgical Oncology (ESSO). He is the founder of the Hellenic Society of Breast Surgeons (HSBS 2000), which he also served as President from 2000 to 2016, when he resigned to focus on UEMS – Division of Breast Surgery, and he was the head of the education, training and clinical trials section of the society. He is also the head professor of the elective course on “Breast Disease and Cancer” for the students of the final year in the Medical School of the National & Kapodistrian University of Athens. Professor Markopoulos is national coordinator and principal investigator in a number of international and national research projects and clinical trials and has published over 300 scientific papers in peer-reviewed international and Greek medical journals with more than 8,000 citations by other authors and a current h-index of 42 and i10-index 132. He has also authored (4) and edited (17) books on breast disease and cancer, including the “European textbook of Breast Cancer management for Surgeons” (Springer 2018), official book of the EBSQ exams in Breast Surgery. He is President of the scientific committee in two Greek Breast Cancer advocacy groups and Europa Donna Hellas. He has organized a large number of national and international postgraduate courses and meetings on breast cancer over the last 30 years, including the 2-day October meeting on the “Advances in Breast Cancer Management”, which he organizes annually since 1996. He has lectured extensively as an invited speaker at national and international congresses. He is the recipient of a number of scientific awards during congresses and honorary awards for his work with breast cancer patients.

See COI

Disease area: Prostate cancer

Biography:
Christophe Massard (MD, PhD), Medical Oncologist, is Chair of the Drug Development Department (DITEP) at Gustave Roussy, Villejuif, France. He is Consultant Medical Oncologist and full time cancer specialist at Gustave Roussy, half time at the Drug Development department (DDD) and joined the faculty in 2006. He is primarily involved in translational cancer research and the design and conduct of early-phase biomarker-driven clinical trials, with a special interest in Genito urinary cancer and Central Nervous System tumour. Dr Massard received his medical degree from PARIS XI University in 2006, and he got a MSc and PhD from PARIS XI University in 2013. He completed his residency training in Paris Hospital, followed by his fellowship in Medical Oncology at Gustave Roussy. He is board certified in Medical Oncology. He did a post-doctoral fellowship in Prof DeBono’s lab at the Royal Marsden Hospital of London and Institute of Cancer Research (London). Dr Massard is member of ESMO, ASCO, AACR. Over the last 5 years, he was the principal investigators of 15 phase I trials, 1 phase II trial (prostate cancer), and sub investigator of more than 80 clinical trials (phase 1 trials and GU cancers). He is also involved in translational research aspects related to Medical Oncology Precision Medicine(MOSCATO, MATCH R and PETRUS program). Dr Massard has contributed to over 180 peer-reviewed publications, including publications in European Urology, Annals of Oncology and Journal of Clinical Oncology. He is also a member of the editorial boards of Bulletin du Cancer, Investigational New Drugs and European Journal of Cancer. Research axes: early clinical trials, precision medicine, GU cancers (prostate cancer, bladder cancer and testis), glioma, and circulating biomarkers.

See COI

Disease area: Breast cancer

Biography:
Icro Meattini is Associate Professor at the Department of Clinical and Experimental Biomedical Sciences of the University of Florence (Florence, Italy), working as Clinical/Radiation Oncologist since 2011 at the Radiation Oncology Unit of the Oncology Department at the Florence University Hospital. He is responsible for the Outpatient Clinics Unit, Clinical Trials Unit, and leader of the Clinical/Radiation Oncology Group of the Breast Cancer Multidisciplinary Team. He is an active member of the European Society for Radiation Oncology (ESTRO), the European Organisation for Research and Treatment of Cancer (EORTC), the European Society of Medical Oncology (ESMO), the Italian Association of Medical Oncology (AIOM), and the Italian Association for Radiotherapy and Clinical Oncology (AIRO). He is actively involved in the ESTRO and EORTC network, past co-Chair of the Breast Working Party (BWP) of the EORTC Radiation Oncology Group (2016-2019) and current member of the EORTC Radiation Oncology Scientific Council (ROSC), current Chair of the BWP of the AIRO, and current Chair of the Clinical Oncology Breast Cancer Group (COBCG) cooperative network. His main fields of interest are focused on breast cancer, systemic therapy integration, multimodal therapies, health-related quality of life, partial breast irradiation, clinical trials development. He is an author of over 150 peer-reviewed international manuscripts. Father of a wonderful young princess, outside of work he loves reading, traveling, and discovering cultures.

See COI

Disease area: Prostate cancer, Bladder cancer, Renal Cell Carcinoma

Biography:
Axel Merseburger is Professor of Urology and Chairman of the Department of Urology at University Hospital Schleswig Holstein, Campus Lübeck, Germany. After graduating from Hannover Medical School in 2002, he carried out a residency in surgery and urology at the Eberhard Karls University, in Tübingen, followed by a research fellowship at the Miller School of Medicine, Miami, USA (2006). He became Associate Professor in 2009 and full Professor in 2012 at Hannover Medical School. Professor Merseburger is a member of various uro-oncology organisations and serves as an advisor for the European Association of Urology (EAU) Guideline Group for Renal Cancer and was the Chairman of the EAU Guideline Group for Lasers and Technologies. He acts as reviewer and editorial board member for several urology and oncology indexed journals and is associate editor of the World Journal of Urology and editor of the Advanced Prostate Cancer Resource Centre. Professor Merseburger’s research activity encompasses both molecular and clinical aspects of uro-oncology, with specific interest in biomarkers and prognostic factors for prostate cancer, renal cell carcinoma and transitional cell carcinoma. He has authored and co-authored >200 peer-reviewed articles and he is the principal investigator in multiple phase II and III clinical trials in Germany.

See COI

Disease area: Breast cancer

Biography:
Professor Ángel Montero Luis is an attending physician at the Radiation Oncology Department of the Clara Campal Integral Oncology Center (CIOCC), University Hospital HM Sanchinarro, Madrid, Spain. He obtained his Radiation Oncology degree in 2000 and his PhD in Medicine and Surgery from the Universidad Autónoma de Madrid in 2004. Ángel Montero Luis is principal investigator and collaborating researcher in several national and international studies. His educational activities include professor in the International Master’s in Clinical Oncology (University of Francisco de Vitoria) and Advanced Technological Applications in Radiation Oncology (University of Murcia), as well as in Higher Technician Training Degree in Radiotherapy and Dosimetry (Center for Biosanitary Professions HM Hospitals). Ángel Montero Luis is coordinator of the Spanish Group of Radiation Oncology in Breast Cancer (GEORM). He is also co-inventor of the IRMAPRON® device, immobilizer for radiotherapy of the breast in the prone position, and co-director of the iOncoR mobile application. He is (co-)author of more than 50 scientific publications and 40 chapters in (inter)national books.

See COI

Disease area: Prostate cancer

Biography:
Dr. Morgans is an Associate Professor of Medicine at Harvard Medical School, a Genitourinary Medical Oncologist and the Medical Director of the Survivorship Program at Dana-Farber Cancer Institute, Boston, MA, USA. As a clinician and investigator, she has expertise in clinical trials and patient-reported outcome measures, as well as incorporating patient preferences and beliefs into clinical decision making. Her research has investigated complications of systemic therapy for prostate cancer survivors, including the study of skeletal, cardiovascular, diabetic, and cognitive complications. Her work has been funded by grants from the Prostate Cancer Foundation, the National Comprehensive Cancer Network, and the US Department of Defense. She leads multiple therapeutic and quality of life focused clinical trials for prostate cancer patients, and has participated in the advanced and localized prostate cancer treatment guidelines committees of the American Urologic Association, and the Cardio-Oncology Committee of American Heart Association.

See COI

Disease area: Bladder cancer

Biography:
Marco Moschini has been working as urologist at San Raffaele Hospital in Milan, Italy since 2021. After receiving his medical degree in 2012 at Vita Salute-San Raffaele University, Milan, he obtained his PhD in 2016 at Universita Magna Graecia in Catanzaro, Italy. Since 2015, he attended 1-year fellowships at the urology departments of the Rochester Mayo Clinic, MN, USA, the General Hospital of Vienna, Austria, and a robotic fellowship at the Montsouris Hospital in Paris, France. He completed his residency program in Luzern, Switzerland, in 2020. Dr. Moschini is the chair of EAU’s Young Academic Urologists’ Urothelial Cancer Group. He has authored more than 250 peer-reviewed articles in international journals and serves as reviewer for more than 30 urological and oncological journals. His main interests focus on urologic oncology, specifically bladder, upper urinary tract and prostate cancers.

See COI

Disease area: Bladder cancer

Biography:
Hugh Mostafid qualified from St Thomas's Hospital London in 1989 and trained at Guy's Hospital and the Institute of Urology in London. He became a Consultant Urologist in 2001 and currently works at the Regional Bladder Cancer Centre at the Royal Surrey County Hospital in Guildford, one of the few centres in the UK performing robotic radical cystectomy. He is also an Honorary Senior Lecturer at the University of Surrey in Guildford where his main research interests are the diagnosis and treatment of bladder cancer. He is a past member of the NICE bladder cancer guidelines group and currently an expert advisor to NICE on bladder cancer. He is also a member of the EAU non-muscle-invasive bladder cancer guideline panel He also is the Chief Investigator for a number of UK bladder cancer trials. He has published over 70 papers and several book chapters on bladder cancer.

See COI

Disease area: Prostate cancer

Biography:
Professor Nicolas Mottet is head of the department of Urology at Centre Hospitalier Universitaire in Saint-Etienne, France and Professor of Surgery at the Jean Monnet University, Saint-Etienne, France. Professor Mottet is board certified in surgery, urology and medical oncology in France. He obtained his MD and his PhD from University Montpellier I. Professor Mottet serves as Chairman of the European Association of Urology Working Group on Prostate Cancer Guidelines, as a board member of the Urology Group for the French Anti-Cancer Centre Federation, and as a member of the International Society of Geriatric Oncology Prostate Cancer Guidelines board. He is also a member of the American Urological Association, the American Society of Clinical Oncology, the European Society for Medical Oncology and the French Urological Association, where he served as Coordinator for the Testis and Penile Cancer Subgroup between 2000 and 2008. He is also a member of the New York Academy of Science. Professor Mottet has published over 160 peer reviewed papers, mainly on urologic oncology and prostatic disorders, and has made numerous presentations and lectures. He is an editorial board member of the European Urology Journal and a reviewer of more than a dozen journals, including the New England Journal of Medicine. He is on the scientific advisory board of several pharmaceutical and biotech companies in urology and oncology drug development and clinical trials and has coordinated or participated to more than 40 clinical studies. Professor Mottet has received several peer reviewed grants and is currently coordinating studies on prostate and bladder cancer.

See COI

Disease area: Renal Cell Carcinoma

Biography:
Stijn Muselaers completed medical school and his residency in Urology at the Radboud University in Nijmegen, the Netherlands. In 2015, he successfully defended his PhD thesis entitled ‘Targeting renal cell with radiolabelled antibodies’. Nowadays, he works as an oncological urologist at the Radboud University Medical Center in Nijmegen with a focus on renal and prostate cancer.

See COI

Disease area: Prostate cancer

Biography:
Dr Omlin is Medical Oncologist specialized in genitourinary oncology working at the Onkonzentrum Zürich in Switzerland. During his career, Dr Omlin has been involved in clinical trials (phase I to phase III), translational research and genitourinary oncology. Dr Omlin is a member of the European Society for Medical Oncology (ESMO) the American Society of Clinical Oncology (ASCO) and currently the president of the genitourinary project group of the Swiss Working Group on Clinical Cancer Research (SAKK). Together with Dr Gillessen he initiated the biennial Advanced Prostate Cancer Consensus Conference (APCCC) in 2015.

See COI

Disease area: Prostate cancer

Biography:
Piet Ost is an associate professor at Ghent University, Ghent, Belgium and radiation oncologist at the Iridium Network, Antwerp, Belgium. He is an expert in the treatment of genitourinary malignancies with a focus on prostate and bladder cancers. His research focuses on the implementation of stereotactic body radiotherapy (SBRT), oligometastases and drug-radiotherapy trials. Dr. Ost has led numerous clinical trials exploring the potential benefit of SBRT for oligometastases and radioimmunotherapy. He serves as a reviewer for several grant organizations and journals. He is a co-author of the ESMO clinical prostate cancer practice guidelines and the 2-yearly Advanced Prostate Cancer Consensus Conference. Dr. Ost is the chair of the Radiation Oncology Scientific Council of the EORTC. He received his M.D. degree at Ghent University in 2006, his PhD in 2011 and completed his radiation oncology training in 2012 at the same university. His clinical and research interests are urological oncology with a specific focus on postoperative prostate cancer radiotherapy and metastasis-directed therapy for oligometastatic prostate cancer. More broadly he implemented stereotactic body radiotherapy (SBRT) for oligometastatic solid tumors at his department and developed a research interest in the combination of SBRT with immunomodulatory agents such as anti-CTLA4 and anti-pd1 antibodies.

See COI

Disease area: Prostate cancer

Biography:
Dr Priyanka Patel is a Clinical Oncology Research Fellow and Trainee at The Royal Marsden NHS Foundation Trust. Dr Patel graduated from Kings College London in 2009 and went on to complete her Fellowship to become a member for the Royal College of Radiology in 2017. She is currently in an out of programme research training post at the Royal Marsden Hospital, her research M.D. focus is on the use of stereotactic body radiotherapy in oligoprogressive disease in metastatic lung and prostate cancer. Dr Patel is due to complete her Clinical Oncology training post in 2023, before becoming a Clinical Oncology Consultant with research interests in the uses of advanced radiotherapy techniques in metastatic cancers.

See COI

Disease area: Renal Cell Carcinoma

Biography:
Dr Lisa Pickering is a Consultant Medical Oncologist who specialises in the treatment of renal, skin and prostate cancers. Dr Pickering gained an honours degree in Physiological Sciences from the University of Oxford in 1992 and her medical degree in 1995 from the University of London. She trained in Medical Oncology at Guy’s and St Thomas’, St George’s and Royal Marsden Hospitals. She was awarded a PhD from the University of London in 2007. She was appointed to St George’s and the Royal Marsden in 2008 as a Consultant Medical Oncologist. At St George’s she was Clinical Lead for Oncology and Palliative Medicine from 2011 and Divisional Chair of Medicine from 2015. She has published more than 30 peer-reviewed papers and has been involved in more than 50 clinical trials. Her major interest is in improving the outcome of renal, skin and prostate cancers. In particular, she is interested in the development of new treatments, determining how to individualise patient treatment and making those advances available to patients.

See COI

Disease area: Prostate cancer

Biography:
Bradley R. Pieters, MD, PhD, is Chair of the Brachytherapy department and Principal Investigator at the Amsterdam University Medical Center, location University of Amsterdam, The Netherlands. Dr. Pieters is the past-chair of the GEC-ESTRO and the Course Director of the European Society for Therapeutic Radiology and Oncology (ESTRO) School for the Comprehensive and Practical Brachytherapy course. Dr. Pieters was trained in Radiation Oncology at the Radboud University Hospital in Nijmegen, The Netherlands, and received his medical degree in 1990. He completed his residency in radiotherapy at Academic Hospital Nijmegen, The Netherlands. Dr. Pieters then completed a brachytherapy fellowship at the Daniel den Hoed clinic in Rotterdam and L'Institut Gustave-Roussy in Villejuif, France. His brachytherapy training was completed at the Academic Medical Center in Amsterdam. Dr. Pieters received his MSc in epidemiology in 2006 and his PhD in 2010 after defending his thesis “Pulsed-dose rate brachytherapy in prostate cancer.” Dr. Pieters’ main field of interest is general brachytherapy with an emphasis on urologic brachytherapy, gynecologic brachytherapy, and translational research for advanced and automatic treatment planning in the field of brachytherapy. Dr. Pieters is currently one of the Principal Investigators of the PROBACH trial (Randomized Phase 3 Study on the Assessment of Late Toxicity by Comparing IMRT High Dose External Beam Radiotherapy Only With External Beam Radiotherapy Combined With HDR or PDR Brachytherapy in Patients With Intermediate/High Risk Prostate Cancer). He is also working on the following research projects: Fast, accurate, and insightful brachytherapy treatment planning for cervical cancer through artificial intelligence; Developing and optimizing the image guided adaptive brachytherapy workflow; The impact of bowel motility on the radiotherapy dose to the bowels.

See COI

Disease area: Breast cancer

Biography:
Dr. Pinker-Domenig is Professor of Radiology and Attending at the Department of Radiology, Breast Service at the Memorial Sloan-Kettering Cancer Center, New York, USA. She is the Head of Translational Imaging Research and Head of Breast MRI (magnetic resonance imaging). She is an expert in translational and clinical breast and oncologic gender imaging. Her research interests focus on molecular breast imaging with advanced high-field/ultra-high-field MRI using multiple advanced MRI parameters and hybrid techniques, such as positron emission tomography (PET)/MRI with specific tracers and the application of artificial intelligence in oncologic imaging to develop imaging biomarkers for precision medicine. Dr. Pinker-Domenig’s research won her 15 competitive grants and 16 research awards. She serves as an Executive Board Member of the European Society of Breast Imaging (EUSOBI), Editor-in-Chief for “British Journal of Radiology Open“, Deputy Editor of the “Journal of Magnetic Resonance Imaging” and is editorial board member in several journals such as of “Insights into Imaging”, “European Radiology”, Radiology: Imaging Cancer and “Breast Care”. She has published more than 180 peer-reviewed papers in breast and oncologic imaging (h-factor 41, https://scholar.google.com/citations?user=h0S3S_MAAAAJ&hl=en).

See COI

Disease area: Prostate cancer

Biography:
Guillaume Ploussard (MD, PhD) is working as uro-oncologist in Toulouse, France, at Saint-Jean Languedoc Hospital and Institut Universitaire du Cancer - Oncopole. After Medical School at the University of Paris, he completed during his training a robotics fellowship at the Department of Urology, McGill University in Canada. His main interests include basic (biomarkers in prostate cancer) and clinical (focal therapy, minimally invasive techniques, fusion biopsies) research that has been funded by research grants in uro-oncology. Guillaume Ploussard is managing editor of World Journal of Urology, section editor of European Urology Today, member of the sub-committee at the EAU section of Oncological Urology, chairman of the EAU working group on prostate cancer and member of the French Cancerology Committe (CC-AFU). He has published more than 160 articles in peer-reviewed journals and received multiple national and international awards for his work.

See COI

Disease area: Breast cancer

Biography:
Philip Poortmans is a radiation oncologist at Iridium Network and associate professor at the University of Antwerp in Antwerp, Belgium, specialised in breast cancer and intraoperative radiation therapy (IORT), including FLASH research. In his previous functions, he was head of the radiation oncology departments of Institut Curie, Paris, France (2017-2019) and of the Radboud university medical centre in Nijmegen, the Netherlands (2014-2017). Since 2017, he is Marie Curie Professor of the Paris Science and Lettres University and Institut Curie in Paris, France. Philip Poortmans obtained his medical degree at the University of Antwerp, Belgium in 1986 and completed his radiation oncology training at the Middelheim and Vincentius Hospitals in Antwerp, Belgium. In 2005, he obtained his PhD degree on quality assurance in breast cancer clinical trials at the University of Maastricht, the Netherlands. He is passionate about teaching, as evident from his role as course director and liaison person for different multidisciplinary courses of the European Society for Radiotherapy and Oncology (ESTRO). Currently, he is also member of the faculty for educational activities of the European Society for Medical Oncology (ESMO), European Society of Surgical Oncology (ESSO) and the European School of Oncology (ESO). Philip Poortmans is an editorial committee member for several international journals and breast cancer guidelines (European Society of Breast Cancer Specialists (EUSOMA), ESTRO, ESMO, St Gallen) and for cancer and pregnancy. He was previously elected president of ESTRO and the European Cancer Organisation (ECCO), among others. He has (co-)authored more than 250 peer-reviewed publications and several book chapters.

See COI

Disease area: Renal Cell Carcinoma

Biography:
Camillo Porta is Chair of Oncology at the Department of Biomedical Sciences and Human Oncology at the University of Bari ‘A. Moro’ in Bari, Italy. He obtained his Medical Degree in 1989 from the University of Pavia, where he specialized in Medical Oncology in 1993. Before his current position, he was Associate Professor of Medical Oncology and Director of the Post-Graduate School of Specialization in Medical Oncology at the University of Pavia and Chief of the Division of Translational Oncology at the IRCCS Istituti Clinici Scientifici Maugeri in Pavia. Dr. Porta’s main clinical and research interests are kidney cancer and the development of novel agents for this disease, for which he is involved in several clinical trials. He has been awarded a prize from Schering-Plough for his experimental work on free radicals, free radical scavengers, and cancer, and the Gaetano Fichera Memorial Prize in Medical Oncology from the University of Pavia. Dr. Porta is a member of the European Society of Medical Oncology (ESMO) Scientific Committee, among various other oncology societies. He has (co-)authored more than 300 publications in peer-reviewed journals and is the Editor-in-Chief of Oncology Reviews.

See COI

Disease area: Prostate cancer

Biography:
Javier Puente was born in Madrid (Spain) in 1977. He received his medical degree in 2001 at the Complutense University of Madrid (Spain) followed by his fellowship in 2002. He received his Advanced Study Accreditation (DEA) degree at Complutense University of Madrid in 2004 while completing the medical oncology program at Hospital Clinico San Carlos, Madrid, under the direction of Professor Eduardo Díaz-Rubio from 2002-2006. Dr. Puente earns his Doctorate in Medicine (PhD) with a mention of “Cum Laude” in 2007 followed by a special prize of doctorate in 2009 at Complutense University of Madrid (Spain). Dr. Puente served as resident in the Medical Oncology Department at Hospital Clinico San Carlos from 2002-2006 at which point he became one of the clinical lead and researcher in the Thoracic, Urinary and Melanoma Cancer Unit. Today, he is the Director of the Institute of Oncology at that hospital. From 2006-2010 he was also Honorific Professor at the Complutense University of Madrid (Spain) where he was named Associate Professor of Medicine in 2011. In 2009, Dr. Puente was named National Medical Advisor at Asociación Española contra el Cáncer (AECC) and Staff Researcher of Clinical Trials Spanish Plattform (CAIBER) at Hospital Clinico San Carlos. He served as a member of the Scientific Board of the Spanish Medical Oncology Society (SEOM) from 2013-2015 and joined the Local Ethics Committee at Hospital Clinico San Carlos in 2015 where he continues to serve as a member. Also, in that year, he became a clinical associated with the Centro Nacional de Investigaciones Oncológicas (CNIO). In addition to SEOM and CNIO, Dr. Puente is also a member of the Spanish Lung Cancer Group (GECP), since 2009, the Spanish Oncology Genitourinary Group (SOGUG), since 2009, the Spanish Group of Orphan and Rare Tumors (GETHI) ,since 2009, and he is a member of the American Cancer Society (ASCO) and European Society of Clinical Oncology (ESMO). Dr Puente has been involved with multiple independent research projects, multiple publications and presented at countless national and international conferences.

See COI

Disease area: Prostate cancer

Biography:
I am a physician specialised in medical oncology involved in clinical research in the field of genitourinary oncology and rare oncological diseases. As medical student, I grow up at IRCCS Istituto Nazionale dei Tumori (in Milan, Italy) and before specialisation, I attended a 1-year fellowship regarding phase I study development. I performed my medical specialisation at the same Hospital in the Genitourinary Oncology Unit. In February 2021, I moved to IRCCS San Raffaele Hospital as consultant in order to reach my research independence, especially in a new preclinical and clinical context. In February 2024, I moved to Royal Marsden Hospital as Locum Consultant in the Genitourinary Unit and Acute Oncology Service (AOS). I am particularly interested in the development of new molecules in phase I, II and III clinical trials in prostate, urothelial cancer of the bladder and upper tract, in germ cell tumours and in penile cancer. As Principal investigator and sub-investigator, this dedicated research activity has made me able to get involved in several multicentre clinical trials, which have contributed to approving new standard of treatment. My scientific interest is also aimed to translational research with particular interest in the study of response and resistance mechanisms to anti-cancer treatments.

See COI

Disease area: Bladder cancer

Biography:
Elie Rassy is a medical oncologist with clinical and research affiliations at Gustave Roussy Cancer Center, one of the world's premier cancer research institutes and Europe’s largest comprehensive cancer center. Dr. Rassy's primary research interests revolve around breast cancer, bladder cancer and cancers of unknown primary, where his profound dedication and expertise have led to the publication of over 230 peer-reviewed articles and several book chapters. Notably, his contributions have been featured in prestigious journals such as Nature, Nature Reviews Clinical Oncology, The Lancet, JAMA Oncology, and Clinical Cancer Research.

See COI

Disease area: Bladder cancer

Biography:
Subodh K. Regmi is an Urologic Oncologist currently working as Assistant Professor at the Department of Urology at University of Minnesota. He has completed his medical education at the Manipal College of Medical Sciences in Nepal, his general surgery and urology training at the All India Institute of Medical Sciences in New Delhi, India, and his urologic oncology fellowship at University of Minnesota in the United States. By working in Nepal, India and the United States, he has gained a diverse urological experience. He is particularly intrigued with non-muscle invasive and muscle invasive bladder cancer, and the multifaceted management of bladder cancer patients. He (co-)authored more than 30 publications.

See COI

Disease area: Prostate cancer

Biography:
Mesut Remzi did his residency and his “Habilitation” at the Medical University of Vienna. Recently he became vice chairman at the Landesklinikum Korneuburg. His clinical activity is uro-oncology, mainly kidney tumors, prostate cancer and upper urinary tract urothelial carcinoma. He is specialised in laparoscopic surgery. Right now he is the primary investigator for an international, multicenter collaborative trial on organ-sparing surgery on upper urinary tract urothelial carcinoma (OSS-UTUC). He is (co)-author of more than one hundred peer-reviewed original articles. He was reviewer of the moth for European Urology and is member as Editor at glace for European Urology, Editor in the World Journal of Urology and reviewer for many urologic journals.

Disease area: Prostate cancer

Biography:
Maria J. Ribal received her medical degree in 1994, followed by her PhD in 2002, both at the University of Barcelona. She attended as Visiting Clinician at Mayo Clinic in Rochester (USA) in 2002. Fellow in Laparoscopic Surgery at the University College London Hospital (UCLH) from June till December 2006. She has been member at the Oncology Unit of the Department of Urology at Fundacio Puigvert (2002-2005). Since February 2005, she is member of the Department of Urology at the University Hospital Clinic of Barcelona. Currently, she is Associated Professor of Surgery at the University of Barcelona. From December 2011 she is the Head of the Uro-Oncology Unit at Hospital Clinic, that comprises a multidisciplinary team: urologists, medical oncologists, radiation oncologists, pathologists, radiologists, nutritionists, nurses and all those involved in the manage and therapy of uro-oncological malignancies. Her main interest is Uro-Oncology and renal transplantation. She is actively involved in translational research in the field of urological malignancies and actively involved in clinical research at the Uro-Oncology Unit She is the author of over hundred international and national publications, 10 book chapters, and > 300 invited lectures at conferences and courses. She is an active member of European Association of Urology (EAU): Member of the Muscle Invasive and Metastatic Bladder Cancer Guidelines Group of the EAU since 2006 and vice-chair since 2018, Member of the EAU section of Uro-Technology (ESUT) since 2010. Board member of the European Urological Scholarship Programme of the EAU (EUSP) since April 2012 and Board Member of the EAU Guidelines Office since January 2016. In 2009, during the EAU Annual Meeting held in Stockholm, she received the Crystal Matula award, a prestigious prize granted to a young promising European urological academician.

See COI

Disease area: Renal Cell Carcinoma

Biography:
Julia Ring obtained her medical degree from the University of Lübeck, Germany in 2015. She is currently a resident of urology at the University Hospital Schleswig-Holstein in Lübeck, Germany and will become a specialist in urology in the summer of 2020. In 2017, she obtained her PhD in gynaecology, entitled: “Early-onset breast cancer: effect of diagnosis and therapy on sexuality, endocrine system and fertility concerns of young mothers in Germany”. Currently, her main clinical and research interests are focussed on kidney and prostate. Julia Ring is a member of the German Association of Urology, the European Association of Urology and the German Society of Residents in Urology. Furthermore, she is participating in a mentoring programme for women of the University Hospital Schleswig-Holstein. She has (co-)authored several peer-reviewed publications.

See COI

Disease area: Renal Cell Carcinoma

Biography:
Sylvie Rottey studied Medicines at the Ghent University in Belgium and is staff member of the department of Medical Oncology (from October 2003). She is head of the department of Medical Oncology at the Ghent University Hospital as well as head of the Drug Research Unit Ghent. She is principle investigator of numerous phase I - III clinical trials since more than 10 years. She is Medical Oncologist and Professor in Pharmacology, certified as Clinical Pharmacologist since 2008 (Dutch Society for Clinical Pharmacology & Biopharmacy). Sylvie Rottey publishes in national and international peer-reviewed journals. She is president ad interim of BSMO, member of ESMO, member of ASCO, board member of VWHHT (https://vwhht.be/), member of EORTC, president of BMUC (https://bmuc.be/), board member of Healixia (https://www.healixia.be/) and member of Eufemed (https://www.eufemed.eu/).

See COI

Disease area: Breast cancer

Biography:
Isabel T. Rubio is the Head of Breast Surgical Oncology at Clinica Universidad de Navarra in Madrid, Spain and Professor of Surgery at the Universidad de Navarra, Spain. She completed her Medical degree at the Faculty of Medicine in Salamanca, Spain, and became a Board-certified General Surgeon. She had additional training for two years as a Breast Surgical Oncology Fellow at The University of Arkansas for Medical Sciences and the Arkansas Cancer Center at Little Rock, USA and for one year at the MD Anderson Cancer Center in Houston, Texas, USA. She completed her PhD in 2000. She is the director of the Breast Surgery Fellowship program at her Institution. Dr. Rubio is active in many societies, founding member and past President of the Spanish Association of Breast Surgeons (AECIMA), EUSOMA President-elect (European Society of Breast Cancer Specialists), Chief Public Affairs of the European Society of Surgical Oncology (ESSO), member of the American Society of Breast Surgeons (ASBrS) and in 2017 member of the Outreach Committee of the Society of Surgical Oncology (SSO). She is breast section editor of the Journal of Surgical Oncology, reviewer for The Breast, and the European Journal of Surgical Oncology. She obtained the European Board of Surgery Qualification in Breast Surgery and, since 2015, is officer at the UEMS Breast Surgery Division and participates as an examiner in the EBSQ Examinations in Breast Surgery. Dr. Rubio is involved as part of the Steering and Executive Committees in several international, multicenter randomized trials. She has received grants to develop her research by the Susan G. Komen Foundation, Spanish Ministry of Health and other institutions. Dr. Rubio has published over 100 national and international peer-reviewed manuscripts and book chapters. She has presented her work in many of the main international meetings in breast cancer. Her interest is in sentinel lymph node biopsy, neoadjuvant treatments, surgical management of BRCA mutation carriers and the role of prognostic markers (genomic profiles, liquid biopsy). Also, her interest is focused on the standardization of breast cancer surgical training and Breast units.

See COI

Disease area: Breast cancer

Biography:
Dr. Salgado is board certified in Anatomical Pathology since 2006. After his graduation as an Anatomical Pathologist, he worked as a consultant Pathologist for the Breast International Group (BIG). As a member of the Aurora Working Group, he helped develop the Aurora Molecular Screening Program for Metastatic Breast Cancer Patients. Currently, he carries out surgical pathology at the Department of Pathology at the GZA/ZNA Hospitals Antwerp, Belgium. He is a scientific collaborator of the Immuno-Task Force of the Breast International Group and an Honorary Research Associate at the Division of Research at the Peter MacCallum Cancer Centre, Melbourne, Australia. Currently, he chairs an International Consortium of Pathologists, namely the “International Immuno-Oncology Biomarkers Working Group” (www.tilsinbreastcancer.org) which develops guidelines for the assessment of immuno-oncological biomarkers in cancer. He works in close collaboration with the EORTC. Dr. Salgado’s strategic views on Oncology have been published in major international high impact factor journals including Nature Reviews Clinical Oncology, Nature Reviews Drug Discovery and Lancet Oncology. His research has been published in Nature, Nature Medicine, Lancet Oncology and Journal of Clinical Oncology, among others. He has developed a specific expertise in the Molecular Pathology of solid tumours, circulating tumour biomarkers, next generation sequencing technologies, validation of biomarkers, innovative clinical trials incorporating genomics, quality assurance of genomic technologies and development of biomarkers in immunotherapeutic trials, with a focus on Tumour Infiltrating Lymphocytes (TILs).

See COI

Disease area: Prostate cancer, Bladder cancer

Biography:
Paul Sargos is a radiation oncologist with strong interest in onco-urology, an area in which he has published more than 60 peer-reviewed articles. He coordinates the GETUG-AFU 30 and GETUG-AFU 17 prospective clinical trials on postoperative radiotherapy of bladder and prostatic tumors, respectively. As an active member of scientific societies such as the GETUG, the AFU, the SFRO in France, as well as the GFRU and the Young-EAU Working Party on Bladder cancer on a European scale, Paul has collaborated with french and international onco-urologic community.

See COI

Disease area: Breast cancer

Biography:
Dr. Cristina Saura is the Head of the Breast Cancer Unit of the Service of Medical Oncology of Vall d’Hebron University Hospital, and Principal Investigator of VHIO’s research group on Breast Cancer and Melanoma since September 2015. Dr. Saura graduated in Medicine from the University of Barcelona (UB) in 2002. From 2003 to 2007 she completed her internship in Medical Oncology at Vall d’Hebron Hospital in Barcelona. In 2007, Dr. Saura obtained her Master in Advanced Studies and Research Aptitude. with the project “Breast Cancer Early Detection Program in High-Risk Women: pilot breast mammography and breast magnetic resonance imaging tracking experience”, with an outstanding grade “A”. Her interest in clinical research led her to complete the Program in Clinical Effectiveness at Harvard School of Public Health in Boston in 2007. She subsequently earned her PhD in Medicine from the Universtat Autonoma of Barcelona (UAB) in 2017 with honors cum laude with the project entitled "Treatment of breast cancer diagnosed during pregnancy". She was awarded a grant of the Strategic Plan for Research and Innovation in Health (PERIS) from the Generalitat de Catalunya in 2018 with the project "Precision medicine in metastatic breast cancer: determination of mutations in tumors and circulating DNA as a guide for the treatment of patients with metastatic breast cancer". Dr. Saura has participated as Principal Investigator and co-investigator in multiple clinical trials in the field of research on breast cancer driven by her interest in the development of new drugs that improve the prognosis of patients. She is currently involved in different international studies with drugs targeted against molecular targets in breast cancer. The work of dr. Saura is focused on precision medicine and she occupies a prominent position in the development of PI3K inhibitors and new anti-HER2 treatments. In the field of pregnancy-related breast cancer, she is currently leading a project on early diagnosis of breast cancer based on the presence of circulating DNA in breast milk. She is the author of multiple publications, as well as communications at different national and international congresses. She is a member of the Scientific Committee and Board of Directors of the cooperative breast cancer group SOLTI, a member of the Spanish Society of Medical Oncology (SEOM), and a member of GEICAM (Spanish Breast Cancer Research Group) and the European and American Oncology Societies (ESMO, ASCO).

See COI

Disease area: Renal Cell Carcinoma

Biography:
After graduating as Medical Doctor from the Medical University of Vienna, Austria in 1992, Prof. Manuela Schmidinger specialised at the same institution in Internal Medicine in 2000 and in Medical Oncology and Haematology in 2002. In 2002, she obtained her venia legendi in Internal Medicine and became Professor of Medicine at the Medical University in Vienna. She specialised in Intensive Care Medicine in 2008 at the Medical University in Vienna. Currently, she is senior physician at the Department of Urology of Medicine at the Medical University of Vienna. She is also Programme Director for renal cell carcinoma and is responsible for the generation of clinical study protocols, basic science in the field of kidney cancer and care of patients with renal cell carcinoma. She is author of more than 100 peer-reviewed papers and contributed to several books (under the name of Schmidinger or former Djavanmard).

See COI

Disease area: Breast cancer

Biography:
Astrid Scholten is a radiation oncologist at The Netherlands Cancer Institute, Antoni van Leeuwenhoek, in Amsterdam. She completed her specialist training at The Leiden University Medical Center in 2006 and remained working there as a radiation oncologist until 2013, when she switched to The Netherlands Cancer Institute in Amsterdam. Her fields of expertise are breast cancer and sarcomas. After gaining her PhD degree in 2005, her research focusses on clinical de-escalation studies in breast cancer. Furthermore, she has a lead role in education and training for specialist registrars.

See COI

Disease area: Breast cancer

Biography:
Carolien Schröder is a medical oncologist, with a focus on breast cancer, at the department of Medical Oncology of the University Medical Center Groningen (UMCG), the Netherlands. She conducts large scale multicenter clinical breast cancer trials within the Netherlands and beyond, and has her own preclinical research line regarding the breast cancer microenvironment. She has procured funding for her research efforts from several sources, including the Dutch Cancer Society. Her research as PI is embedded in the Cancer Research Center Groningen, the Netherlands. After her thesis ‘New ways to optimize breast cancer treatment’ (2001), her residency Internal Medicine (2006) and fellowship Medical Oncology (2008), she was appointed as staff member at the department of Medical Oncology of the UMCG, and associate professor at the Rijksuniversiteit Groningen, the Netherlands. As research fellow, she worked in Fox Chase Cancer Center, Philadelphia (lab of Prof. Thomas Hamilton) and at Harvard Medical School, Dana Farber Cancer Center, Boston, USA (with Prof. Eric Winer and Dr. Beth Overmoyer). Schröder’s research focus is to explore novel rational treatment options to enhance therapeutic efficacy and personalized medicine, in interdisciplinary, translational research. This has led to breast cancer research regarding preclinical and clinical intervention strategies directed at the breast cancer microenvironment and metastases, early clinical trials with novel anticancer agents, as well as large scale registration and translational trials for rare subgroups, including male and inflammatory breast cancer. It has also led to preclinical and clinical molecular imaging studies, with regard to visualization of tumor-specific targets, including cancer drug targets. She received a Clinical Research Award from the Dutch Cancer Society for her grant application: Molecular imaging to guide targeting the breast cancer microenvironment. She is member of several institutional and (inter)national boards including the Dutch Cancer Society Scientific Board and the French Institute National du Cancer Scientific Board. She is involved in national breast cancer guideline development. She is involved in national and international collaboration networks, including Institute Jules Bordet in Brussels, Belgium and the Dana-Farber Cancer Institute in Boston, MA, USA. She is member of international research consortia regarding male breast cancer and inflammatory breast cancer. She is currently supervising 8 PhD students and has published over 90 scientific publications (H-score: 25) including 25 publications as first or senior author. Since 2008, she received a total budget of 5 million euro from different institutions (including Dutch Cancer Society, Dutch Pink Ribbon Foundation) as main applicant and 11,6 million euro as co-applicant. Carolien Schröder is an all-round academic medical oncologist, board certified in Internal Medicine and Medical Oncology. She participates in all aspects of clinical care in the department of Medical Oncology: outpatients, clinic, and consultations. She participates in training of MD students, internal medicine residents and medical oncology fellows. She holds a university teaching qualification from the University of Groningen. As an acknowledged opinion leader in the field of breast cancer, she has a particular interest in reflecting and explaining oncology developments for various audiences including professionals, patients and lay people.

See COI

Disease area: Bladder cancer

Biography:
To be added

See COI

Disease area: Breast cancer

Biography:
Professor Christos Sotiriou graduated from the Medical School of the Université Libre de Bruxelles (ULB) in Brussels, Belgium and obtained his Medical Oncology Specialization in 1999. He completed his PhD in genomics in 2004. Currently, he is Professor in the Medical Department of Medical Oncology at the Jules Bordet Institute and Research Director at the National Fund for Scientific Research (FNRS) in Belgium. He is the head of the Breast Cancer Translational Research Laboratory at the Jules Bordet Institute. His main research focus consists of improving the molecular understanding of breast cancer biology, disease dissemination and progression using state-of-the art “omics” technologies, as well as in developing prognostic and predictive biomarkers for breast cancer. The ultimate goal is to accelerate the translation of basic science discoveries dedicated to breast cancer into the clinic. Professor Sotiriou was Member of the TransALTTO committee of the Breast International Group (BIG) and an Executive Chair/Co-organizer/Member of the Executive Committee of the IMPAKT international conference (2009 to 2017). He is currently member of several scientific committees for international meetings, including SABCS, AACR, EBCC, ECCO and ESMO. He served as advisory council member of the Susan G. Komen for the Cure from 2010 to 2016 and an elected member of the scientific council of the International Agency for Research on Cancer (IARC - World Health Organization) from 2012 to 2016. He was elected as Fellow of the European Academy of Cancer Sciences in October 2010 and associated editor of Annals of Oncology since 2014. He is also a core Faculty Member of the European School of Oncology since 2017. Professor Sotiriou’s work has resulted in several patents and in over 250 original research publications, including numerous papers in New England Journal of Medicine, Nature, Nature Medicine, PNAS, JNCI, Journal of Clinical Oncology and Lancet Oncology. He is the recipient of several prestigious national and international awards.

See COI

Disease area: Prostate cancer

Biography:
Dr Martin Spahn is currently Senior Consultant at the Center of Urology at the Hirslanden Klinik Zürich, Prostate Cancer Center Hirslanden Zürich. He is Prof. of Urology at the university of Essen, Germany. His professional career started in Germany where he was born: he graduated in Medicine in 1993 and specialized in Urology and Surgical Urology in 2001 at the University of Mannheim. In 2007 he was appointed Adjunct Clinical Head at the Department of Urology of the Community Hospital Karslruhe, Germany and from 6/2007 on at the Department of Urology and Pediatric Urology at the University Hospital in Würzburg, Germany where he worked until 2012 before moving to the Inselspital Bern, University Hospital, Bern, Switzerland. Dr Spahn is member of several scientific societies, including AUA, EAU. He serves as member of the Steering Committee of the Genito-Urinary Group of the EORTC since 2013. He is PI (Principal Investigator) of a large translational Research project (SPECTApros), an EORTC Reseach platform. He has published over 100 papers in peer-reviewed journals. Dr Spahn is reviewer for several journals including European Urology, British Medical Journal, Journal of Urology and serves as a grant reviewer for several scientific organisations in europe including Cancer Research UK, German Cancer League and Swiss National Fund. He received several awards for his translational resarch in high risk Prostate Cancer including the Prostate Cancer Research Award of the EAU in 2015 and the Urological Oncology Award of the EAU in 2011.

See COI

Disease area: Prostate cancer

Biography:
Daniel Spratt, MD, is the Vincent K. Smith Chair of the Department of Radiation Oncology at University Hospitals Seidman Cancer Center, Cleveland, OH, USA and a Professor and Chair of Radiation Oncology at Case Western Reserve University School of Medicine, Cleveland, USA. Dr. Spratt completed his medical training at Vanderbilt University and residency training in Radiation Oncology at Memorial Sloan Kettering Cancer Center. He joined the faculty at the University of Michigan in 2015 and became the fastest tenured Professor in the University’s history in 2020. While at the University of Michigan he was the Chief of the Genitourinary Radiotherapy Program, Director of Spine Oncology, and co-Chair of the Genitourinary Clinical Research Team for the Rogel Cancer Center. Dr. Spratt joined UH Seidman Cancer Center and the Case Comprehensive Cancer Center (CCCC) in 2021 where he serves as the Chair for the Department of Radiation Oncology and co-PI of the CCCC NCTN LAPS grant. Dr. Spratt is an international expert in prostate cancer, clinical trial design, and biomarker development and validation. He serves as the Chair of the Intact Prostate Cancer Subcommittee within NRG Oncology, member of the NCCN prostate cancer guidelines committee as a special invited biomarker expert, member of the National Cancer Institute’s Genitourinary Steering Committee, and ad hoc expert for the FDA’s Oncologic Drugs Advisory Committee. He runs an NIH funded translational research team focused on the development and validation of prognostic and predictive biomarkers, has published over 350 peer-reviewed manuscripts, and has served as the principal investigator on numerous national and international clinical trials. He has mentored over 40 students, residents, fellows, and faculty, and has received numerous teaching and mentorship awards.

Disease area: Prostate cancer

Biography:
Dr. Stephenson is Professor of Urology and Director of Urologic Oncology at Rush University Medical Center in Chicago, IL, USA. He completed his medical school at the University of Western Ontario, London, ON, Canada, followed by residency training in urology at McGill University in Montreal, QC, Canada. Following this, he completed a fellowship in urologic oncology at Memorial Sloan-Kettering Cancer Center, New York, NY, USA. He was Director of Urologic Oncology at Cleveland Clinic, Cleveland, OH, USA, for 14 years before joining Rush University in 2019. His clinical and research interests are in the management of localized and recurrent prostate cancer, and germ cell tumors. He is chair of the American Urologic Association and the American Society for Clinical Oncology (AUA/ASCO) Testicular Cancer Guidelines Committee, and authors chapters on prostate cancer and testicular cancer in Campbell-Walsh-Wein Urology. He has authored over 200 articles in the peer-reviewed literature and has received grant support from the Robert Wood Johnson Foundation, the Urology Care Foundation, and the American Cancer Society.

Disease area: Bladder cancer

Biography:
Dr. Cora Sternberg is Full Professor of Medicine and the Clinical Director of the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York-Presbyterian Hospital, NY, USA. A graduate of the University of Pennsylvania undergraduate and medical schools, she completed her fellowship and was on staff at Memorial Sloan Kettering Cancer in NY. Dr. Sternberg is an internationally respected leader in the fields of medical oncology and urological malignancies and a recognized expert in the area of new drug development. She is the principal investigator for numerous studies and an internationally respected researcher who has lectured extensively at universities and cancer symposia worldwide. Dr. Sternberg is particularly known for her influential work in bladder cancer and for her publications on novel therapies for prostate cancer and targeted agents in renal cell carcinoma. Dr. Sternberg has published extensively (more than 513 articles, 6 textbooks) and is an associate editor and editorial board member of several international journals and is a member of the European School of Oncology (ESO) core faculty. Dr. Sternberg was also elected chairman of the nominating committee of ASCO’s board of directors. Lastly, she acts as the liaison between the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York-Presbyterian, New York, and the Meyer Cancer Centre, bridging innovative research and clinical practice.

See COI

Disease area: Prostate cancer

Biography:
Dr. Johan Stranne is an associate professor at the Sahlgrenska Academy, Gothenburg University and a senior consultant at the Department of Urology at the Sahlgrenska University Hospital, Gothenburg, Sweden. He obtained his medical degree from the University of Lund, Sweden in 1997. Following a 2-year internship in Trollhättan, he received his medical licence in 1998. Afterwards, he became a resident at the Department of Urology at the Sahlgrenska University Hospital in Gothenburg. He was accredited as specialist in urology in 2003, and he passed the European Board of Urology specialist exam in Urology (FEBU) in 2004. He has been active as a consultant in urology in the Sahlgrenska University Hospital ever since. Dr. Stranne’s clinical research focuses on treatment of localised prostate cancer with a minimization of side effects. In 2006, he obtained his PhD from the University of Gothenburg with a dissertation about inguinal hernia after urological surgery in males, with specific reference to radical retropubic prostatectomy. He published several peer-reviewed articles on this topic, as well as on robot-assisted radical prostatectomy, PSA-screening, LUTS and ED. Currently, Dr. Stranne is doing research in several clinical studies on prostate cancer and radical prostatectomy, such as the SPCG 15 (RCT of RT + HT vs RP of locally advanced PC), SPCG 17 (active surveillance), the Gothenburg 2 study (PSA-screening) and the LAPPRO-study (prospective comparison RRP vs RALP). Dr. Stranne is member of several national and international urological societies, such as the Scandinavian Prostate Cancer Group (SPCG), European Association of Urology and the Swedish Urological Association.

See COI

Disease area: Prostate cancer

Biography:
Dr. Michiel Strijbos is a Consultant Medical Oncologist at the AZ Klina hospital in Brasschaat, Antwerp. He was trained at Leuven University in Belgium and the Erasmus University in Rotterdam, The Netherlands, where he graduated in 2004. Between 2004 and 2009, he enrolled in a PhD project focusing on tumor vasculature at the Daniel den Hoed Cancer Center in Rotterdam, for which he was awarded a PhD. Dr. Strijbos received his board certification in Medical Oncology in 2014. In his daily practice, Dr. Strijbos focuses on the research and treatment of genitourinary malignancies, as well as sarcoma. He is currently active in several task forces and committees with regards to GU malignancies and is a principal investigator in several clinical trials in this field. He is also a member of the ESMO GU Faculty, EORTC GU group, and serves as an associate editor for the ESMO Open GU section, and co-authored several book chapters related to GU malignancies.

See COI

Disease area: Renal Cell Carcinoma

Biography:
Dr Suárez received her MD in Medicine and Surgery in 2001 at the Autonomous University of Barcelona, Spain. She obtained a Specialist Training in Medical Oncology at the Faculty of Medicine, Autonomous University of Barcelona—Hospital del Mar. In 2008, she joined the Oncology Department of Vall d’Hebron University Hospital as physician (attending staff) of the Genitourinary, Central Nervous System, Sarcoma and Tumors of Unknown Origin Program. In 2018, she completed her doctoral studies cum laude with her doctoral thesis entitled “Prognostic value of genetic alterations in the mTOR pathway of patients with metastatic renal cell carcinoma treated with mTOR inhibitors”. Since 2008, Dr Cristina Suárez has been the Co-investigator and Principal Investigator in several clinical trials related to genitourinary malignancies. She is also the (co-)author of more than 80 national and international scientific papers, posters and book chapters, especially focused in the area of genitourinary tumors.

See COI

Disease area: Bladder cancer, Renal Cell Carcinoma

Biography:
Bernadett Szabados is a consultant urological surgeon at the University College Hospital and a senior clinical researcher at Barts Cancer Institute, both in London, UK. She trained in several European cities including Brussels, Belgium, and Munich, Germany. Her interests span from basic laboratory research to clinical trials in urological malignancies, including but not limited to, renal and transitional cell carcinoma with the goal of individualising and improving care and treatment. Dr Szabados has participated in over 20 international, randomised phase 3 trials and has been involved in the process leading to the regulatory approval of axitinib/pembrolizumab in kidney cancer and maintenance avelumab in bladder cancer. Dr Szabados is a member of the European Association of Urology (EAU), European Society for Medical Oncology (ESMO), and International Bladder Cancer Network (IBCN), and a co-author of the ESMO Bladder Cancer guidelines. She has contributed to more than 30 peer-reviewed publications.

See COI

Disease area: Renal Cell Carcinoma

Biography:
To be added.

See COI

Disease area: Prostate cancer, Bladder cancer, Renal Cell Carcinoma

Biography:
PD Dr. Arnoud J. Templeton is a staff medical oncologist at the Department of Medical Oncology St. Claraspital Basel, Switzerland, and group leader oncological and general research. Dr. Templeton graduated in medicine at the university of Basel and gained his MD in 2003. He completed his medical training in St. Gallen with the Swiss board certification in Internal Medicine and Medical Oncology. He attended the Flims Workshop Methods in Clinical Cancer Research in 2008 and did a clinical research fellowship at the Princess Margaret Cancer Centre in Toronto 2012-2014 under the supervision of Professor Ian Tannock. He was a staff medical oncologist at the Department of Medical Oncology Kantonsspital St. Gallen and worked for the Swiss Group for Clinical Cancer Research (SAKK) as Medical Advisor before accepting his current position. › His major clinical and research interest is urogenital malignancies and markers of host inflammation. Dr. Templeton has published more than 100 peer reviewed articles and is a regular reviewer for several journals. Dr. Templeton is a member of a number of societies, including the European Society of Medical Oncology (ESMO), and the Swiss Medical Association (FMH). His major clinical and research interest is prostate cancer and markers of inflammation. He has been co-investigator in several phase I – III trials and is co-principle investigator of a large multicentre trial conducted in Switzerland and has published more than 90 peer-reviewed articles as author or co-author. Dr. Templeton is a regular reviewer for various oncologic and urologic journals and is a member of the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the Swiss Group for Clinical Cancer Research (SAKK), and the Swiss Medical Association (FMH).

See COI

Disease area: Prostate cancer, Renal Cell Carcinoma

Biography:
Dr. Camilla Thellenberg Karlsson is a senior consultant at the Department of Oncology, Cancercentrum at Umeå University Hospital and a PhD researcher at the Department of Radiation Sciences, Oncology at Umeå University. She obtained her medical degree from the University of Umeå in 1997 followed by an 2-year internship in Sundsvall to provide for the medical licence in 1998. After that she returned to Umeå and became resident at the Department of Oncology, Cancercentrum at Umeå University Hospital. Following this path she became accredited as a specialist in Oncology 2006 and has ever since worked as a consultant and focused her clinical work on Uro-oncology, mainly Prostate Cancer. The research questions were first focused on genetic epidemiology and her thesis was defended in 2008. After that focus has mainly been on clinical studies trying to improve treatment for both localised and disseminated prostate cancer. She is at present Process leader of Prostate Cancer in the Northern region of Sweden and Head of the Swedish Uro-Oncology Society as well as a board member of the international urological society, Scandinavian Prostate Cancer Group SPCG.

See COI

Disease area: Prostate cancer

Biography:
Dr. Derya Tilki is an Associate Professor of Urology at the Martini-Klinik Prostate Cancer Center and Department of Urology, University Hospital Hamburg-Eppendorf in Germany specializing in prostate cancer. Dr. Tilki completed her urology residency training at the Ludwig-Maximilans-University in Munich. She subsequently completed a clinical fellowship in Urologic Oncology at UC Davis in Sacramento. After completion of her training she joined the Faculty at the Martini-Klinik Prostate Cancer Center. Dr. Tilki is on the Editorial Board for European Urology and the British Journal of Urology International. She has published over 200 peer-reviewed articles and 4 book chapters. Dr. Tilki is an Associate Editor of European Urology Focus.

See COI

Disease area: Prostate cancer

Biography:
Professor Bertrand Tombal is Chairman of the Division of Urology and Professor of Urology at the Université catholique de Louvain (UCL), Cliniques universitaires Saint-Luc, Brussels, Belgium. He is member of the Belgian Royal Academy of Medicine. He is the Member of the Board of European Organization for Research and Treatment in Cancer (EORTC), the leading European academic research organization in the field of cancer. He has both a basic science and a clinical interest in urological oncology, particularly in the field of prostate and bladder cancer. Professor Tombal obtained his MD in 1990 and his PhD in 2003, both from the Université catholique de Louvain. During his PhD, he studied the mechanisms involved in apoptosis of prostate cancer cells and the modulation of apoptosis by growth factors. He completed part of his basic sciences training at Johns Hopkins University, Baltimore, MD, USA. Professor Tombal’s primary clinical interest is the treatment of advanced stages of prostate cancer, and particularly hormonal treatment and development of new biological agents. He is heading the uro-oncology division at the Université catholique de Louvain where he is coordinating several trials in this research area. In addition, Professor Tombal has authored many published papers, books, and book chapters. He has presented at numerous national and international conferences and has been the recipient of various awards for his research in the field of urology, including the European Association of Urology thesis award, which he received in 2003. Professor Tombal is also member of Belgium College of Oncology, the Skeletal Care Academy, and member of the Scientific Office of European Association of Urology.

See COI

Disease area: Prostate cancer

Biography:
Jeffrey J. Tosoian, MD, MPH is an Assistant Professor of Urology at the Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center (VUMC/VICC), Nashville, TN, USA. He completed medical school and urology residency at Johns Hopkins University, Baltimore, MD, USA, where he obtained a Master of Public Health (MPH) in epidemiological and biostatistical methods for clinical research. He then completed a translational research and clinical fellowship in urologic oncology at the University of Michigan, Ann Arbor, MI, USA. Dr. Tosoian sees urologic cancer patients at the VUMC/VICC and Nashville Veterans Affairs (VA) Medical Center. His research is focused on the development and clinical application of diagnostic and prognostic tools, including blood-, urine-, and tissue-based biomarkers, to guide detection and management of genitourinary cancers. His research has been supported by the National Cancer Institute Specialized Program of Research Excellence (SPORE) Career Enhancement Program, the Prostate Cancer Foundation, and the National Institutes of Health and the National Cancer Institute (NIH/NCI) Early Detection Research Network.

See COI

Disease area: Prostate cancer

Biography:
Levent Türkeri MD, PhD is a Professor of Urology at Acıbadem University School of Medicine in İstanbul, Turkey. He is a Uro-oncologist with expertise in robotic, laparoscopic and open surgery. His research interest involves molecular aspects of diagnosis and prognostic factors of urological malignancies along with clinical trials. Currently, he is serving as the Board member of Urooncology Association of Turkey, Director of School of Urology and Coordinator of Board of Urology at Society of Urological Surgeons (Turkey) and also actively involved in a number of national and international urological societies such as AUA, EAU, URS, AAEU, ESOU, ESUR, EORTC. Area of Expertise: Urooncology (Prostate Cancer, Bladder Cancer, Kidney Cancer, Testis Cancer), Urologic Surgery (open, laparoscopic, robotic surgery), Molecular Urology

See COI

Disease area: Renal Cell Carcinoma

Biography:
Jean-Paul Arnoldus van Basten is urologist, with special interest in minimal invasive and robotic surgery, at the Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands. He received his MD in 1996 at the University of Maastricht. During his study he resided at the University hospital in Medan, Sumatra and did research on typhoid perforation in Kumasi, Ghana. He wrote his thesis entitled ‘Sexual sequelae of testicular cancer’ at the departments of Urology and Surgical Oncology at the University of Groningen. He received his PhD degree in 1999. Dr van Basten has received awards from the Dutch Urological Society as recognitions for his publications and presentations. In 1998 he started his residency in general surgery at the University Hospital in Maastricht and was recruited for Urology in 2001. His residency in urology was continued at the Isala Clinics in Zwolle and University of Groningen. In 2003 Dr van Basten started a fellowship in laparoscopy at the Radboud University and Jeroen Bosch Hospital in the Netherlands. Moreover, he stayed two weeks in New York visiting the Memorial Sloan Kettering Cancer Center. He did a mini-fellowship in robotic surgery at the University of Los Angeles. Dr van Basten is a member of several scientific societies including the European Association of Urology and is a board member of the Dutch Society of Endo-Urology. He is the editor-in-chief of the book ‘Dutch recommendations in laparoscopic and robotic surgery in urology’, which forms the theoretical basis of the exam in laparoscopic skills for Dutch residents. Dr van Basten is actively involved in teaching residents and fellows in laparoscopic and surgery and is official proctor in robotic surgery. He supervises several PhD students and is value-based healthcare lead in prostate cancer of the Santeon hospital alliance. He is proud to be involved in the Mirrors of Medicine programme.

See COI

Disease area: Prostate cancer, Bladder cancer, Renal Cell Carcinoma

Biography:
Jeroen van Moorselaar studied Medicine at the University of Nijmegen in the Netherlands and obtained his medical degree in June 1987. He continued his career as research fellow in the urological research laboratory of the Urology Department at the University Hospital in Nijmegen where he did his PhD entitled ‘Cytokine Therapy in Experimental Urological Cancer’ in 1991. He was certified as urologist in June 1997. From that time he has worked in the University Hospital in Nijmegen in the Urological Department and in April 1998 he moved to the University Hospital in Utrecht where he worked until August 2005. In September 2005 he became the head of the Urological Outpatient Department at the VU University Medical Centre in Amsterdam where he still works, but since August 2008 in the position of Chairman. In March 2011 he was appointed as Professor of Urology. He is member of various national and international organizations. He is member of the Dutch working party on urological oncological guidelines and is founding member of the Dutch UroOncology Studygroup. Since May 2007 he is board member of the European School of Urology. Furthermore he is Incoming President of the European Board of Urology. He is an active researcher in the field of Urological Oncology. He has published over 180 peer reviewed papers and book chapters.

See COI

Disease area: Prostate cancer

Biography:
Dr. Inge van Oort completed her urological training at het Radboud University Nijmegen Medical Centre, the Netherlands, in 2006. In that same year she started her fellowship in oncological urology and she also became part of the faculty at the Radboud University Nijmegen Medical Centre (chairman: Peter Mulders). In 2008 she was appointed as an oncological urologist and senior staff member. In 2009, she obtained her PhD on the clinical relevance of pathological findings after radical prostatectomy at the department of Urology at the Radboud University Nijmegen Medical Centre. Her main interest in oncological urology is the (surgical) treatment of prostate and bladder cancer. In research she has interests in finding new molecular markers in prostate cancer and in the treatment of castration resistant prostate cancer. She also has been part of several large trials in CRPC (i.e Cougar 301 and 302 (abiraterone), Proselica and compassionate use program (cabazitaxel), Affirm and Previal (enzalutamide), provenge (sipuleucel-T), orteronel. On national level she has been part of several activities at the Dutch Urological Society(DUA). She was the chair of the working group on Oncological Urology (WOU) for 7 years, member of the board of education for residents (CCO), and member of the “Quality of care” group. She is member of the multidisciplinary Dutch guideline group on prostate cancer. At the EAU she’s a member of the EAU Guideline Office- new media group and was part of the Young academic Urologists (prostate cancer group) from 2011-2014. In 2013 she received a grant from the Dutch cancer foundation for a study on Quality of care in prostate cancer treatment and in 2015 a grant from the ZonMW for a study on tumor response markers in combination with drug exposure measurement. Inge M. van Oort is member of national and international urological and oncological associations. She is also reviewer for national and international journals and member of the editorial board of the world journal of Urology.

See COI

Disease area: Renal Cell Carcinoma

Biography:
Charles Van Praet is a urologist at Ghent University Hospital in Belgium. He received his medical degree in 2012. He completed his PhD in 2017 with a thesis on “Novel treatments in prostate cancer”. After finishing his residency in urology in 2019, he became a fellow of the European Board of Urology. He is a member of national and international associations. His main focus is treatment of prostate and kidney cancer and minimal-invasive surgery. Currently, he is an investigator in multiple clinical and academic trials.

See COI

Disease area: Prostate cancer

Biography:
Neha Vapiwala, MD FACR FASTRO is Professor, Vice Chair of Education and Co-Chief of Genitourinary (GU) Oncology in the Department of Radiation Oncology, and Dean of Admissions at the Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA, USA. Her research interests focus on biological and technological improvements in the delivery of photon- and proton-based radiation, molecular imaging, and translational work to elucidate mechanisms of cancer-related fatigue. She is the Principal Investigator of multiple National Cancer Institute (NCI)-funded therapeutic trials for prostate cancer, including the randomized phase III INDICATE trial, which explores the clinical value of positron emission tomography (PET)-directed systemic and metastasis-directed therapy in patients with post-prostatectomy recurrence. Dr. Vapiwala also serves on multiple national and cooperative group committees in GU oncology, including the NCI Prostate Cancer Task Force and the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) GU Early Modality committee in the role of Co-Chair. She is an inductee of the Academy of Master Clinicians, an elected officer on the American Society for Radiation Oncology's Board of Directors, and an appointed member of the editorial boards of Journal of Clinical Oncology and Journal of American Medical Association (JAMA) Oncology. In addition to being a leader in the field of GU oncology, Dr. Vapiwala has a strong interest in medical education. She was an Assistant Dean of Student Affairs prior to her current Admissions leadership role, and has served on the Executive Committee of the national Association of Directors of Radiation Oncology Programs and as Chair of the national Accreditation Council for Graduate Medical Education's Residency Review Committee.

See COI

Disease area: Bladder cancer

Biography:
To be added

See COI

Disease area: Prostate cancer

Biography:
Jochen Christoph Walz, MD is the head of the Department of Urology at the Institut Paoli-Calmettes Cancer Centre in Marseille, France. He was chairman of the EAU Section of Urological Imaging from 2009 to 2017. Dr. Walz attended the Medical School of the University of Mainz, Germany. He completed his dissertation at the University of Mainz about “Mechanisms of mutagenesis of ultimate geno-toxique substances influenced by homogenate of human erythrocytes”. Afterward, he completed his residency in Urology at the University of Marseille, France and Hamburg, Germany. He is board certified urologist since 2005. He became a research fellow at the Cancer Prognostics and Health Outcomes Unit at the University of Montreal, Canada in 2006-2007 and received his “Habilitation” in 2008 in Urology at the University of Hamburg, Germany. He is specialized in urooncology and urological imaging.

See COI

Disease area: Prostate cancer

Biography:
To be added

See COI

Disease area: Breast cancer

Biography:
Hans Wildiers is a medical oncologist dedicated to breast cancer research and geriatric oncology. He is staff member at the Department of Medical Oncology in the University Hospital Leuven, Belgium since 2004. He coordinates the Leuven Multidisciplinary Breast Centre since 2015. He has been coordinator of several academic studies in the field of breast cancer and geriatric oncology, and author of more than 250 peer-reviewed papers. He has been active within the board of SIOG, the international society of geriatric oncology, for many years, and serves this organisation as president from November 2018 until October 2020. From 2009 until 2015, he has chaired the elderly task force ‘Cancer in Elderly’ of the European Organisation of Research and Treatment of Cancer (EORTC).

See COI

Disease area: Breast cancer

Biography:
Dr. Zeidan is Associate Professor of Radiation Oncology and residency program director at the American University of Beirut. He received his dual MD/PhD degree from the Medical University of South Carolina in 2009. This was followed by four years of residency training in Radiation Oncology at Stanford University (2010-2014) where he served as Chief Resident (2013-2014). He was appointed as Assistant Professor of Radiation Oncology at the University of Miami (2014-2016) where he directed the radiobiology program. Along with several other co-investigators, he authored more than 30 peer-reviewed publications in the field. This work was recognized by several grants and awards from the radiological society of North America (RSNA) and the American Society for Radiation Oncology (ASTRO).

See COI

Disease area: Prostate cancer

Biography:
Prof. Thomas Zilli is head of the Radiation Oncology Department at the Oncology Institute of Southern Switzerland (IOSI - EOC) in Bellinzona, Switzerland, and Professor at Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Switzerland and at the Faculty of Medicine of the University of Geneva, Switzerland. He graduated in Medicine in 2004 at University of Udine (Italy) and specialized in Radiation Oncology at the Geneva University Hospital, Switzerland. Main research includes the treatment of genitourinary tumors using stereotactic radiotherapy techniques as well as the use of molecular imaging in the radiotherapy planning. He is principal investigator or co-investigator of several trials exploring the role of extracranial stereotactic body radiotherapy in different disease sites. He is also actively involved in the GFRU society (Groupe Francophone de Radiothérapie en Urologie) and active member of the ESTRO, EORTC, and SAKK.

See COI